| Q93612557 | Q93612557 |
| Q95359087 | Q95359087 |
| Q33398789 | "I should live and finish it": a qualitative inquiry into Turkish women's menopause experience |
| Q82236809 | 'Gain'-ful insight into the cardiomyocyte Ca²⁺ seX factor |
| Q46877678 | 1 and 2 mg 17beta-estradiol combined with sequential dydrogesterone have similar effects on the serum lipid profile of postmenopausal women |
| Q34274447 | 17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload |
| Q46755244 | 17Beta-estradiol attenuates PDGF signaling in vascular smooth muscle cells at the postreceptor level |
| Q37170186 | 17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women |
| Q44120832 | 17Beta-estradiol inhibits the adhesion of leukocytes in TNF-alpha stimulated human endothelial cells by blocking IL-8 and MCP-1 secretion, but not its transcription |
| Q39373446 | 17Beta-estradiol/levonorgestrel transdermal system for the management of the symptomatic menopausal woman |
| Q51740951 | 17Beta-oestradiol partially attenuates the inhibition of nitric oxide synthase-3 by advanced glycation end-products in human platelets. |
| Q44886443 | 17beta-estradiol inhibits cyclic strain-induced endothelin-1 gene expression within vascular endothelial cells |
| Q37286111 | 17beta-estradiol prevents early-stage atherosclerosis in estrogen receptor-alpha deficient female mice |
| Q43515037 | 17beta-estradiol, gender independently, reduces atheroma development but not neointimal proliferation after balloon injury in the rabbit aorta |
| Q89820452 | 17β-Estradiol Inhibits PCSK9-Mediated LDLR Degradation Through GPER/PLC Activation in HepG2 Cells |
| Q44638594 | 17β-Estradiol inhibits cardiac fibroblast growth through both subtypes of estrogen receptor |
| Q39276387 | 17β-estradiol protects human skin fibroblasts and keratinocytes against oxidative damage |
| Q78251271 | 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial |
| Q33585615 | 2-Methoxyestradiol ameliorates glucose tolerance with the increase in β-cell mass in db/db mice |
| Q34300668 | 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. |
| Q56970799 | 2007 ESH‐ESC Guidelines for the management of arterial hypertension |
| Q22241922 | 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines |
| Q40079780 | 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen |
| Q34762182 | 27-Hydroxycholesterol: the first identified endogenous SERM |
| Q42165328 | A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine |
| Q53230202 | A Canadian observational study of the optimal method of transition from postmenopausal hormone therapy to raloxifene. |
| Q57821897 | A Causally Naïve and Rigid Population Model of Disease Occurrence Given Two Non-Independent Risk Factors |
| Q36543436 | A Comparison of Statin Therapies in Hypercholesterolemia in Women: A Subgroup Analysis of the STELLAR Study |
| Q57157080 | A Heartfelt Message, Estrogen Replacement Therapy: Use It or Lose It |
| Q57055224 | A Statistical Perspective on Prevention Trials: A View from the Women’s Health Initiative |
| Q78167467 | A case of fatal pulmonary thromboembolism associated with the use of intravenous estrogen therapy |
| Q34223276 | A case-control study on the effect of hormone replacement therapy on ischaemic heart disease |
| Q34495746 | A comparison of clinical outcome studies among cholesterol-lowering agents |
| Q43776120 | A comparison of the effects of two continuous HRT regimens on cardiovascular risk factors |
| Q28346596 | A complex role for the progesterone receptor in the response to vascular injury |
| Q33544854 | A critical European view of the HERS trial |
| Q35068814 | A cross-sectional and 10-year prospective study of postmenopausal estrogen therapy and blood pressure, renal function, and albuminuria: the Rancho Bernardo Study |
| Q43992057 | A cross-sectional study of the effects of hormon replacement therapy on the cardiovascular disease risk profile in healthy postmenopausal women |
| Q44215610 | A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events |
| Q34113070 | A longitudinal study of serum lipoproteins in relation to endogenous reproductive hormones during the menstrual cycle: findings from the BioCycle study |
| Q43683067 | A look to the future: new treatment guidelines and a perspective on statins |
| Q44346168 | A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate |
| Q48251318 | A novel approach for correction of crosstalk effects in pathway analysis and its application in osteoporosis research |
| Q43917968 | A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function |
| Q57225591 | A population-based cohort study of HRT use and breast cancer in Korea |
| Q36461942 | A proposed key escrow system for secure patient information disclosure in biomedical research databases |
| Q45368959 | A prospective, case-control study on the lipid profile and the cardiovascular risk of menopausal women on oestrogen plus progestogen therapy in a northern Italy province. |
| Q84458613 | A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored |
| Q53141728 | A randomized, double-blind, placebo-controlled study of the effect of a Chinese herbal medicine preparation (Dang Gui Buxue Tang) on menopausal symptoms in Hong Kong Chinese women. |
| Q44245840 | A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women |
| Q37638712 | A review of the cardiovascular and breast actions of drospirenone in preclinical studies |
| Q34474654 | A review of the physical and metabolic effects of cross-sex hormonal therapy in the treatment of gender dysphoria |
| Q46093207 | A selective estrogen receptor modulator inhibits TNF-alpha-induced apoptosis by activating ERK1/2 signaling pathway in vascular endothelial cells |
| Q103001995 | A systematic review and meta-analysis of effects of menopausal hormone therapy on cardiovascular diseases |
| Q61813376 | A systematic review and meta-regression analysis to examine the 'timing hypothesis' of hormone replacement therapy on mortality, coronary heart disease, and stroke |
| Q34207956 | A systematic review of randomized trials of disease management programs in heart failure |
| Q34133879 | A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data |
| Q30491831 | A theory of eu-estrogenemia: a unifying concept |
| Q34612394 | A “window of opportunity:” The reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent |
| Q34175518 | ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Pat |
| Q33751623 | ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft [...] |
| Q59356505 | ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M |
| Q77853784 | ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stab |
| Q44442664 | ACOG recommendation for HRT doesn't withstand scientific scrutiny |
| Q33647497 | ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy |
| Q35839121 | Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats |
| Q35666086 | Activation of GPR30 inhibits cardiac fibroblast proliferation |
| Q90741012 | Activation of PI3K/Akt pathway mediated by estrogen receptors accounts for estrone-induced vascular activation of cGMP signaling |
| Q37098920 | Activation of Peroxisome Proliferator-activated Receptor γ (PPARγ) and CD36 Protein Expression: THE DUAL PATHOPHYSIOLOGICAL ROLES OF PROGESTERONE |
| Q29347039 | Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats |
| Q35867653 | Activation of estrogen receptor-alpha reduces aortic smooth muscle differentiation |
| Q24618363 | Activation of the annexin A1 pathway underlies the protective effects exerted by estrogen in polymorphonuclear leukocytes |
| Q38997170 | Acute Coronary Syndromes: Differences in Men and Women |
| Q35582529 | Acute and chronic effects of oestradiol on left ventricular diastolic function in hypertensive postmenopausal women with left ventricular diastolic dysfunction |
| Q44165707 | Acute effects of transdermal 17beta-estradiol on hemostatic variables after 24-hour treatment |
| Q55306808 | Acute myocardial infarction in young women: current perspectives. |
| Q47563183 | Addition of Estradiol to Cross-Sex Testosterone Therapy Reduces Atherosclerosis Plaque Formation in Female ApoE-/- Mice. |
| Q33663800 | Adenosine A1 receptor activation increases myocardial protein S-nitrosothiols and elicits protection from ischemia-reperfusion injury in male and female hearts |
| Q36502941 | Adipose tissue, insulin resistance and low-grade inflammation: implications for atherogenesis and the cardiovascular harm of estrogen plus progestogen therapy |
| Q41886145 | Aerobic exercise for vasomotor menopausal symptoms: A cost-utility analysis based on the Active Women trial |
| Q51041956 | Aerobic physical training increases contractile response and reduces cardiac fibrosis in rats subjected to early ovarian hormone deprivation. |
| Q36295227 | Aetiology and management of male erectile dysfunction and female sexual dysfunction in patients with cardiovascular disease |
| Q36380206 | Age alters cerebrovascular inflammation and effects of estrogen |
| Q50166085 | Age at Menarche and Gallstone Disease in Middle-Aged Women |
| Q44568625 | Age at menopause and mortality in Japan: the Jichi Medical School Cohort Study |
| Q60923926 | Age of Postmenopause Women: Effect of Soy Isoflavone in Lipoprotein and Inflammation Markers |
| Q36030921 | Age-dependent reductions in mitochondrial respiration are exacerbated by calcium in the female rat heart |
| Q35784175 | Age-related changes in testosterone and the role of replacement therapy in older men. |
| Q36844120 | Age-related differences in cardiac ischemia-reperfusion injury: effects of estrogen deficiency |
| Q73161349 | Age-specific differences in the use of thrombolytic therapy and hospital outcomes in patients with acute myocardial infarction: a community-wide perspective |
| Q35659388 | Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study |
| Q36864696 | Ageing, oestrogen, platelets and thrombotic risk |
| Q34038237 | Aging negatively affects estrogens-mediated effects on nitric oxide bioavailability by shifting ERα/ERβ balance in female mice. |
| Q28387247 | Aging, estrogen loss and epoxyeicosatrienoic acids (EETs) |
| Q35122109 | Alcohol use and prognosis in patients with coronary heart disease |
| Q34321427 | Alcohol-a universal preventive agent? A critical analysis |
| Q28354188 | Alterations in EDHF-mediated hyperpolarization and relaxation in mesenteric arteries of female rats in long-term deficiency of oestrogen and during oestrus cycle |
| Q89482547 | An emerging perspective on sex differences: Intersecting S-nitrosothiol and aldehyde signaling in the heart |
| Q30431416 | An intensive behavioral weight loss intervention and hot flushes in women |
| Q34719941 | An update on hormone replacement therapy: health and medicine for women: a multidisciplinary, evidence-based review of mid-life health concerns. |
| Q34635752 | Androgen deficiency: menopause and estrogen-related factors |
| Q26771962 | Androgen receptor (AR) in cardiovascular diseases |
| Q45215913 | Androgen receptor gene expression in leucocytes is hormonally regulated: implications for gender differences in disease pathogenesis |
| Q37600356 | Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling |
| Q58134737 | Androgen therapy in the aging male: assessing the effect on heart disease |
| Q43518215 | Androgenic anabolic steroids and arterial structure and function in male bodybuilders |
| Q35145586 | Androgens and the ageing male and female |
| Q58159348 | Androgens and the risk of cardiovascular disease |
| Q38009706 | Androgens for postmenopausal women's health? |
| Q35573885 | Andropause: To treat or not to treat? |
| Q33706038 | Angina and its treatment |
| Q37210143 | Anti-Atherosclerotic Effects of a Phytoestrogen-Rich Herbal Preparation in Postmenopausal Women. |
| Q37424924 | Anti-aging medicine: pitfalls and hopes. |
| Q43748772 | Anti-ischemic effect of chronic oestrogen replacement therapy alone or in combination with medroxyprogesterone acetate in different replacement schemes |
| Q34289602 | Antiaging therapy: an overview |
| Q34727160 | Antiatherosclerosis interventions in women |
| Q34272156 | Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. |
| Q42743106 | Antiproliferative effect of estrogen in vascular smooth muscle cells is mediated by Kruppel-like factor-4 and manganese superoxide dismutase |
| Q35610515 | Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology |
| Q74587128 | Approach to symptomatic coronary disease in the elderly: TIME to change? |
| Q44506565 | Are pharmacological considerations of relevance in hormone replacement therapy for prevention of chronic disease? |
| Q44011033 | Are polymorphisms in oestrogen receptors genes associated with lipid levels in response to hormone therapy? |
| Q38398327 | Are there cognitive and neurobehavioural correlates of hormonal neuroprotection for women after TBI? |
| Q43014562 | Are there sex differences in risk factors for coronary heart disease? Maternal versus paternal transmission |
| Q36946008 | Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved |
| Q34661852 | Aromatase inhibitors and inactivators for breast cancer therapy |
| Q94563760 | Arterial palmar arch occlusion in a woman with Raynaud's disease taking oral combined menopausal hormone therapy: A case report |
| Q34329552 | Assessing the role of oestrogen in the prevention of cardiovascular disease |
| Q53632681 | Assessment of coronary flow reserve and microcirculation: a clinical perspective. |
| Q80149206 | Assessment of hypercoagulability markers and lipid levels in postmenopausal women undergoing either oral or transdermal hormone replacement therapy |
| Q38021775 | Assessment of low-density lipoprotein targets |
| Q45023683 | Assessment of risk factors in coronary patients being followed by cardiologists: control of risk factors in coronary patients |
| Q43994989 | Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone |
| Q33539483 | Assessment of the risk for venous thromboembolism among users of hormone replacement therapy |
| Q44714692 | Associated response in bone and lipids during hormone replacement therapy |
| Q55491652 | Association between blood pressure and retinal arteriolar and venular diameters in Chinese early adolescent children, and whether the association has gender difference: a cross-sectional study. |
| Q57947570 | Association between methodological characteristics and outcome in health technology assessments which included case series |
| Q51723665 | Association between promoter and coding region mutations of UDP-glucuronosyltransferase 1A1 and beta-thalassemia/Hb E with cholelithiasis. |
| Q37281210 | Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence |
| Q37240444 | Association of Age at Menopause With Incident Heart Failure: A Prospective Cohort Study and Meta-Analysis |
| Q48515064 | Association of Androgen Deprivation Therapy and Thromboembolic Events: a Systematic Review and Meta-Analysis |
| Q73849738 | Association of circulating cellular adhesion molecules with menopausal status and hormone replacement therapy. Time-dependent change in transdermal, but not oral estrogen users |
| Q74180629 | Association of postmenopausal hormone replacement therapy with carotid atherosclerosis and soluble thrombomodulin: the vascular aging (EVA) study. Etude du Vieillissement Artériel |
| Q33867562 | Associations of endogenous sex hormones with the vasculature in menopausal women: the Study of Women's Health Across the Nation (SWAN). |
| Q39744513 | Astragalin, a Flavonoid from Morus alba (Mulberry) Increases Endogenous Estrogen and Progesterone by Inhibiting Ovarian Granulosa Cell Apoptosis in an Aged Rat Model of Menopause. |
| Q33595279 | Atherogenesis and iron: from epidemiology to cellular level |
| Q97527174 | Atheroprotective effects of 17β-oestradiol are mediated by peroxisome proliferator-activated receptor γ in human coronary artery smooth muscle cells |
| Q37801387 | Atherosclerosis and sex hormones: current concepts |
| Q34707888 | Atherosclerosis imaging methods: assessing cardiovascular disease and evaluating the role of estrogen in the prevention of atherosclerosis |
| Q33986377 | Atherosclerotic vascular disease: management of angina in the office setting |
| Q43573541 | Attenuation of endothelin-1 induced vasoconstriction by 17beta estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease |
| Q77890375 | Attenuation of heart-rate variability in postmenopausal women on progestin-containing hormone replacement therapy |
| Q50986104 | Attitudes of women who are currently using or recently stopped estrogen replacement therapy with or without progestins: results of the AWARE survey. |
| Q36278168 | Attitudes toward hormone replacement therapy in the new millennium: university physicians' and patients' perspectives |
| Q52163013 | Attitudes towards hormone replacement therapy among middle-aged women and men. |
| Q45119253 | Augmented sympathetic vasoconstriction in exercising forearms of postmenopausal women is reversed by oestrogen therapy |
| Q37350367 | Autonomic Cardiovascular Damage during Post-menopause: the Role of Physical Training. |
| Q37210869 | Baroreflex sensitivity varies during the rat estrous cycle: role of gonadal steroids |
| Q44228334 | Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial |
| Q37248714 | Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries |
| Q44000453 | Beneficial effects of hormonal replacement therapy on chromium status and glucose and lipid metabolism in postmenopausal women |
| Q58738994 | Bergamot Polyphenol Fraction Exerts Effects on Bone Biology by Activating ERK 1/2 and Wnt/β-Catenin Pathway and Regulating Bone Biomarkers in Bone Cell Cultures |
| Q57338270 | Bewertung des Risikos für Bias in kontrollierten Studien |
| Q43693246 | Beyond the cholesterol profile: monitoring therapeutic effectiveness of statin therapy |
| Q43659682 | Beyond the null hypothesis--do the HERS results disprove the estrogen/coronary heart disease hypothesis? |
| Q44087175 | Bias as a threat to the validity of cancer molecular-marker research |
| Q38888165 | Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism |
| Q37976087 | Bioactive compounds with effects on inflammation markers in humans. |
| Q37190890 | Bioidentical hormone therapy: Nova Scotia pharmacists' knowledge and beliefs |
| Q34900490 | Bioidentical hormones for menopausal therapy |
| Q37921312 | Biomarkers for predicting postmenopausal coronary heart disease |
| Q37065520 | Black cohosh and St. John's wort (GYNO-Plus) for climacteric symptoms |
| Q35162714 | Blood pressure, arterial function, structure, and aging: the role of hormonal replacement therapy in postmenopausal women |
| Q47685507 | Blunting of cardioprotective actions of estrogen in female rodent heart linked to altered expression of cardiac tissue chymase and ACE2. |
| Q36597571 | Body composition and bone mineral density after ovarian hormone suppression with or without estradiol treatment |
| Q94086323 | Bon sens fondé sur des données probantes? |
| Q44864645 | Breast Cancer Incidence and Hormone Replacement Therapy in Canada |
| Q34938322 | Breast cancer after use of estrogen plus progestin in postmenopausal women |
| Q44957319 | Breast cancer incidence trends in Norway--explained by hormone therapy or mammographic screening? |
| Q34581334 | Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status |
| Q35572432 | Breast cancer prevention trials using retinoids |
| Q24793143 | Bridging case-control studies and randomized trials |
| Q33945555 | Bridging the treatment gap. |
| Q34704488 | Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis |
| Q28192240 | C-reactive protein and cardiovascular disease: a review of risk prediction and interventions |
| Q47182880 | C-reactive protein and coronary artery disease: influence of obesity, caloric restriction and weight loss |
| Q34287715 | CME Paper: Hormone Replacement Therapy for Prevention or Treatment of Atherosclerosis in Postmenopausal Women: Promises, Controversies, and Clinical Trials |
| Q44640274 | Calcium Channel Blockers (Felodipine) and Pediatric Essential Hypertension |
| Q35017905 | Can a healthy endothelium influence the cardiovascular effects of hormone replacement therapy? |
| Q35018656 | Can current electronic systems meet drug safety and effectiveness requirements? |
| Q44300317 | Cardiac norepinephrine release: modulation by ovariectomy and estrogen |
| Q51730823 | Cardioprotection in female rats subjected to chronic volume overload: synergistic interaction of estrogen and phytoestrogens. |
| Q34585847 | Cardioprotective benefits of hormone replacement therapy |
| Q33984342 | Cardioprotective effects of ovarian hormones and the HERS in perspective |
| Q36402654 | Cardioprotective strategies to improve long-term outcomes following coronary artery bypass surgery |
| Q30743765 | Cardiovascular Disease in Women: Clinical Perspectives |
| Q89993571 | Cardiovascular Risk/Benefit Profile of MHT |
| Q91613788 | Cardiovascular Risks Associated with Gender and Aging |
| Q35767456 | Cardiovascular actions of selective estrogen receptor modulators and phytoestrogens |
| Q43089068 | Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy |
| Q54972686 | Cardiovascular consequences of hormone therapy in postmenopausal women: Messages to clinicians. |
| Q44651073 | Cardiovascular disease and lipids. Issues and evidence for the management of dyslipidaemia in primary care |
| Q36536188 | Cardiovascular disease and osteoporosis: balancing risk management. |
| Q74603701 | Cardiovascular disease and risk factor epidemiology: a look back at the epidemic of the 20th century |
| Q37346122 | Cardiovascular disease in older women: a challenge in diagnosis and treatment |
| Q34707877 | Cardiovascular disease in postmenopausal women: myths and reality |
| Q39175755 | Cardiovascular disease in women, is it different to men? The role of sex hormones |
| Q37269396 | Cardiovascular disease prevention tailored for women |
| Q37180867 | Cardiovascular effects of medroxyprogesterone acetate and progesterone: a case of mistaken identity? |
| Q34132714 | Cardiovascular effects of oestrogens |
| Q34669339 | Cardiovascular effects of raloxifene: the potential for cardiovascular protection in women |
| Q31797579 | Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. |
| Q43015198 | Cardiovascular effects of testosterone: implications of the "male menopause"? |
| Q36872073 | Cardiovascular effects of tibolone: a selective tissue estrogenic activity regulator |
| Q90206721 | Cardiovascular health and the menopausal woman: the role of estrogen and when to begin and end hormone treatment |
| Q36561352 | Cardiovascular health and the menopause: the gynecologist as the patients' interface |
| Q37994253 | Cardiovascular health in the menopausal woman: impact of the timing of hormone replacement therapy |
| Q33742238 | Cardiovascular pharmacology of hormone replacement therapy |
| Q73893653 | Cardiovascular protection by postmenopausal hormone replacement therapy -- the point of lower oestrogen dosages |
| Q34377353 | Cardiovascular protective effects of 17beta-estradiol metabolites |
| Q38871997 | Cardiovascular risk assessment in women - an update. |
| Q40436937 | Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study |
| Q36106647 | Cardiovascular risk factors and menstrual cycle phase in pre-menopausal women |
| Q36723824 | Cardiovascular risk in women: the impact of hormone replacement therapy and prospects for new therapeutic approaches |
| Q45260501 | Cardiovascular risks under hormone replacement therapy |
| Q36582624 | Cardiovascular safety profiles of aromatase inhibitors : a comparative review. |
| Q60953865 | Carnosic Acid Modulates Increased Hepatic Lipogenesis and Adipocytes Differentiation in Ovariectomized Mice Fed Normal or High-Fat Diets |
| Q44000445 | Carotid intima-media thickness in surgical menopause: women who received HRT versus who did not. |
| Q46152923 | Case-only analysis of treatment-covariate interactions in clinical trials |
| Q35100170 | Causes of death and associated risk factors among climacteric women from Southern Brazil: a population based-study |
| Q30249320 | Cautionary tales in the interpretation of observational studies of effects of clinical interventions. |
| Q46359743 | Celecoxib affects estrogen sulfonation catalyzed by several human hepatic sulfotransferases, but does not stimulate 17-sulfonation in rat liver |
| Q43748768 | Cell cycle analysis and detection of proliferative cell nuclear antigen of the endometrium after hormone replacement therapy |
| Q43651101 | Cerebral embolism and hormone replacement therapy |
| Q33336527 | Cerebral venous thrombosis associated with tentorial subdural hematoma during oxymetholone therapy |
| Q34040240 | Challenges associated with peripheral arterial disease in women |
| Q39710440 | Changes in attitudes, knowledge and hormone replacement therapy use: a comparative study in two random samples with 6-year interval |
| Q43906729 | Changes in cardiovascular disease risk factors among American Indians. The Strong Heart Study |
| Q81163509 | Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy |
| Q34704799 | Changes in newspaper coverage about hormone therapy with the release of new medical evidence |
| Q24658107 | Changes in postmenopausal hormone replacement therapy use among women with high cardiovascular risk |
| Q37237180 | Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women |
| Q46936650 | Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: a mechanism for cardiovascular toxicity and benefit? |
| Q42167610 | Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study |
| Q33282313 | Changes of the prescription of hormone therapy in menopausal women: an observational study in Taiwan |
| Q61911444 | Chapter 20 Epidemiological implications of primary and secondary stroke prevention |
| Q33710365 | Characteristics and recent evolution of menopausal hormone therapy use in a cohort of Swedish women |
| Q74319254 | Chemoprevention of breast cancer |
| Q36106730 | Chemotherapy-induced ovarian failure: manifestations and management |
| Q44527967 | Cholesterol-fed ovariectomized monkeys are good animal models for human atherosclerosis of postmenopausal women |
| Q37104653 | Chronic black tea extract consumption improves endothelial function in ovariectomized rats |
| Q37928906 | Chronic kidney disease in postmenopausal women |
| Q46683006 | Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women |
| Q51434541 | Circulating sex hormones modulate vascular contractions and acute response to 17β-estradiol in rat mesenteric arteries. |
| Q35103077 | Clinical and laboratory evaluation of thrombophilia |
| Q36072505 | Clinical appraisal of the Women's Health Initiative |
| Q34727203 | Clinical cardiovascular studies of hormone replacement therapy |
| Q46877675 | Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer |
| Q45212706 | Clinical efficacy of EH0202, a Kampo formula, on the health of middle-aged women |
| Q46728267 | Clinical guide to the menopause and post-menopause |
| Q77903427 | Clinical implications of endothelial dysfunction |
| Q36575429 | Clinical practice in Turner syndrome. |
| Q74812292 | Clinical relevance of the HERS trial |
| Q36599365 | Clinical trial design issues: at least 10 things you should look for in clinical trials |
| Q36684575 | Clinical trials bureaucracy: unintended consequences of well-intentioned policy |
| Q33706972 | Clinical trials, consensus conferences, and clinical practice |
| Q35676656 | Clinical trials: active control vs placebo--what is ethical? |
| Q73667499 | Clinical trials: introduction |
| Q43823428 | Clustering of traditional risk factors and precocity of coronary disease in women |
| Q34130749 | Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience |
| Q44234540 | Cognitive effects of estrogens in women with cardiac disease: what we do not know. |
| Q45960420 | Cognitive effects of short-term use of raloxifene: a randomized clinical trial. |
| Q37728394 | Combination of raloxifene, aspirin and estrogen as novel paradigm of hormone replacement therapy in rabbit model of menopause |
| Q35838501 | Combined antihypertensive and lipid-lowering treatment |
| Q92127319 | Combined but not single treatment with ethinylestradiol/levonorgestrel and spironolactone reduces plasminogen activator inhibitor-1 in insulin-resistant ovariectomised rats |
| Q43922726 | Combined hormone replacement therapy improves endothelial function in healthy postmenopausal women |
| Q42920762 | Combined hormone therapy at menopause and breast cancer: a warning--short-term use increases risk |
| Q44028328 | Combined oral estradiol valerate-norethisterone treatment over 3 years in postmenopausal women: effect on lipids, coagulation factors, haematology and biochemistry |
| Q73543358 | Commentary on the Women's Health Initiative |
| Q37345825 | Common beta-adrenergic receptor polymorphisms are not associated with risk of sudden cardiac death in patients with coronary artery disease |
| Q26740253 | Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile? |
| Q34275967 | Comorbidity in rheumatoid arthritis. |
| Q36974411 | Comparative effects of dydrogesterone and medroxyprogesterone acetate in critical areas: the brain and the vessels |
| Q44653729 | Comparative effects of tamoxifen and angiotensin II type-1 receptor antagonist therapy on the hemodynamic profile of the ovariectomized female rat |
| Q35114092 | Comparative evaluation of raloxifene versus estrogen: Progestin on symptomatology, endometrium, and lipid profile in postmenopausal women |
| Q34195727 | Comparative safety of bone remodeling agents with a focus on osteoporosis therapies |
| Q50715984 | Comparison between phytoestrogens and estradiol in the prevention of atheroma in ovariectomized cholesterol-fed rabbits. |
| Q43814222 | Comparison of pharmacokinetic profiles of a 17 beta-estradiol gel 0.6 mg/g (Gelestra) with a transdermal delivery system (Estraderm TTS 50) in postmenopausal women at steady state |
| Q56087724 | Comparison of the effects of a new conjugated oral estrogen, estradiol-3β-glucoside, with oral micronized 17β-estradiol in postmenopausal women |
| Q40742855 | Comparison of the effects of continuous combined and sequential combined medroxyprogesterone acetate-estradiol treatment on the proliferation of MCF-7 cells |
| Q46132720 | Comparison of the effects of new and conventional hormone replacement therapies on left ventricular diastolic function in healthy postmenopausal women: a Doppler and ultrasonic backscatter study |
| Q77779548 | Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles |
| Q92644749 | Complement activation in the arteries of patients with severe atherosclerosis |
| Q34107328 | Complete and selective estrogenic effects on lipids and cardiovascular disease |
| Q37650744 | Complexities of oestrogen in stroke |
| Q47637530 | Compliance with oral HRT in postmenopausal women in clinical trials--meta analysis |
| Q48166851 | Comprehensive primary prevention of cardiovascular disease in women. |
| Q47556269 | Comprehensive review of cardiovascular toxicity of drugs and related agents. |
| Q36126565 | Concordance of Results from Randomized and Observational Analyses within the Same Study: A Re-Analysis of the Women's Health Initiative Limited-Access Dataset. |
| Q51544036 | Concurrent use of simvastatin and estrogen--progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women. |
| Q59433974 | Confronting the challenges of the menopausal transition |
| Q55982498 | Conjugated Equine Estrogen, Esterified Estrogen, Prothrombotic Variants, and the Risk of Venous Thrombosis in Postmenopausal Women |
| Q46378676 | Conjugated equine estrogen, raloxifene and arterial stiffness in postmenopausal women |
| Q74774174 | Consequenses for HRT following the HERS II and WHI reports: the primum non nocere is important, but translation into quo vadis is even more essential |
| Q34627378 | Considerations for treating dyslipidemia in special diabetic populations |
| Q34191632 | Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation |
| Q34254664 | Controversial issues in climacteric medicine (I) Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop, 13-16 October 2000, Royal Society of Medicine, London, UK. |
| Q34575162 | Controversial issues in climacteric medicine I. Cardiovascular disease and hormone replacement therapy. International Menopause Society Expert Workshop. 13-16 October 2000, royal society of medicine, London, UK. |
| Q40732072 | Coronary Artery Disease in Postmenopausal Women |
| Q34022283 | Coronary Heart Disease in Postmenopausal Women with Type II Diabetes Mellitus and the Impact of Estrogen Replacement Therapy: A Narrative Review. |
| Q46127863 | Coronary Heart Disease in Women: Hormone Replacement Therapy |
| Q84631304 | Coronary artery disease in men: the role of sex hormones |
| Q28219423 | Coronary artery disease in women: a review on prevention, pathophysiology, diagnosis, and treatment |
| Q37604591 | Coronary artery disease in women: an unsolved dilemma |
| Q22248005 | Coronary heart disease and hormone replacement therapy after the menopause |
| Q33626048 | Coronary heart disease in women: a challenge for the 21st century |
| Q36433568 | Coronary heart disease in women: highlights of the past 2 years--stepping stones, milestones and obstructing boulders |
| Q40393652 | Coronary heart disease in women: what do we know now? |
| Q35834128 | Coronary heart disease risk reduction in postmenopausal women: the role of statin therapy and hormone replacement therapy |
| Q38538168 | Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation |
| Q37408791 | Correlation between insulin-induced estrogen receptor methylation and atherosclerosis |
| Q37609391 | Cost implications of new evidence on prevention of cardiovascular disease |
| Q36648725 | Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model |
| Q42760392 | Could recent decreases in breast cancer incidence really be due to lower HRT use? Trends in attributable risk for modifiable breast cancer risk factors in Canadian women. |
| Q34169103 | Counseling postmenopausal women about bioidentical hormones: ten discussion points for practicing physicians |
| Q61800270 | Critical Care Aspects of Gallstone Disease |
| Q54565667 | Crucial role of phospholamban phosphorylation and S-nitrosylation in the negative lusitropism induced by 17β-estradiol in the male rat heart. |
| Q36141272 | Culture and symptom reporting at menopause. |
| Q64936707 | Current and future burden of venous thrombosis: Not simply predictable. |
| Q36675379 | Current breast cancer risks of hormone replacement therapy in postmenopausal women |
| Q33860933 | Current concepts in secondary prevention after acute myocardial infarction |
| Q36144183 | Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women |
| Q34506784 | Current medical therapies for patients with peripheral arterial disease: a critical review |
| Q38125941 | Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects |
| Q33993678 | Current, new and future treatments in dyslipidaemia and atherosclerosis |
| Q24792815 | Debate: Should the elderly receive thrombolytic therapy or primary angioplasty? |
| Q24792867 | Debate: The potential role of estrogen in the prevention of heart disease in women after menopause |
| Q24792878 | Debate: The potential role of estrogen in the prevention of heart disease in women after menopause |
| Q24792578 | Debate: The slippery slope of surrogate outcomes |
| Q82859669 | Decline in US breast cancer rates after the Women's Health Initiative: socioeconomic and racial/ethnic differentials |
| Q42964146 | Decline in breast cancer incidence due to removal of promoter: combination estrogen plus progestin |
| Q37250420 | Declining breast cancer incidence and decreased HRT use. |
| Q37600007 | Decreased Renal Function Is a Risk Factor for Subclinical Coronary Atherosclerosis in Korean Postmenopausal Women. |
| Q44505661 | Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease |
| Q51476885 | Dehydroepiandrosterone protects against oxidative stress-induced endothelial dysfunction in ovariectomized rats. |
| Q37673237 | Depressive behavior and coronary artery atherogenesis in adult female cynomolgus monkeys |
| Q35757843 | Design and Rationale for the Study of Changes in Iron and Atherosclerosis Risk in Perimenopause |
| Q57910256 | Design and baseline characteristics of a trial on health effects of soy protein with isoflavones in postmenopausal women |
| Q34397332 | Design and conduct of clinical trials in hormone replacement therapy |
| Q43730182 | Design and methods of the Raloxifene Use for The Heart (RUTH) study |
| Q46827248 | Determinants of the differences in LDL-cholesterol after initiation of statin treatment |
| Q46716308 | Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects |
| Q34743117 | Determination of the clinical importance of study results |
| Q36905197 | Detrimental effects of endogenous oestrogens on primary acute myocardial infarction among postmenopausal women |
| Q43718360 | Developing a clinical strategy for cholesterol management in an era of unanswered questions |
| Q34107453 | Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure |
| Q35019031 | Development of a miniature, low-dose, frameless intrauterine levonorgestrel-releasing system for contraception and treatment: a review of initial clinical experience |
| Q34288061 | Developments in the management of menopause and hormone replacement therapy: a presentation given at the symposium to honour the retirement of Professor Martin Vessey |
| Q79091211 | Diabetes and Heart Disease |
| Q77616770 | Diabetes mellitus and cardiovascular disease |
| Q33942348 | Diabetic dyslipidaemia: current treatment recommendations |
| Q34755683 | Diagnosis and management of lipoprotein abnormalities |
| Q36493454 | Diagnosis and management of peripheral artery disease in women |
| Q38912710 | Diagnosis and risk stratification of women with stable ischemic heart disease |
| Q34520972 | Diagnosis and treatment of osteoporosis |
| Q30671838 | Did you know? Hormone Replacement Therapy and Heart Disease: Plausible Mechanisms and Observational Studies Yield to Hard Data |
| Q33916897 | Dietary soy-derived isoflavone phytoestrogens. Could they have a role in coronary heart disease prevention? |
| Q45841349 | Differences Between Gynecologists and Primary Care Physicians in Hormone Therapy Prescribing: Why They Matter |
| Q43561565 | Differences in hormone replacement therapy use by social class, region and psychological symptoms. |
| Q21254698 | Differences in menopausal hormone therapy use among women in Germany between 1998 and 2003 |
| Q33541716 | Different methods for administering 17beta-estradiol to ovariectomized rats result in opposite effects on ischemic brain damage |
| Q44427519 | Differential Regulation of Proteasome-Dependent Estrogen Receptor α and β Turnover in Cultured Human Uterine Artery Endothelial Cells |
| Q33595324 | Differential effects of medroxyprogesterone acetate on thrombosis and atherosclerosis in mice |
| Q73298961 | Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women |
| Q40587819 | Differential effects of raloxifene and estrogen on insulin sensitivity in postmenopausal women |
| Q39839966 | Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method |
| Q46660405 | Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers |
| Q46542073 | Differential regulation of insulin resistance and hypertension by sex hormones in fructose-fed male rats |
| Q44512688 | Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women |
| Q38658378 | Digitalis use and lung cancer risk by histological type in men. |
| Q34165126 | Direct effects of estrogen on the vessel wall |
| Q46686778 | Discharge prescription for ischemic stroke patients |
| Q35856372 | Discontinuation of hormone replacement therapy after myocardial infarction and short term risk of adverse cardiovascular events: nationwide cohort study |
| Q80166353 | Discontinuation of menopausal hormone therapy: what are the symptoms and how should they be managed? |
| Q44050559 | Discontinuation of postmenopausal hormone therapy in a Massachusetts HMO. |
| Q36088805 | Discontinuing hormone replacement therapy: attenuating the effect on CVD risk with lifestyle changes |
| Q34008254 | Discussion of hormone replacement therapy between physicians and their patients |
| Q40714159 | Disparities in hormone replacement therapy use by socioeconomic status in a primary care population |
| Q34262645 | Divergent approaches to the treatment of dyslipidemia with low levels of high-density lipoprotein cholesterol |
| Q73226857 | Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management |
| Q43702211 | Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin |
| Q35918601 | Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling |
| Q50904374 | Do Finnish women using hormone replacement therapy need more information about risks. |
| Q35549339 | Do patients with osteoarthritis get the clinical research they need? |
| Q43612147 | Do women using hormone replacement treatment have less pre-existing cardiovascular risk |
| Q81353106 | Does estrogen therapy reduce coronary artery calcification in postmenopausal women? |
| Q73298628 | Does hormone replacement therapy in menopause have a cardiovascular benefit? |
| Q37427428 | Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit?: Myocardial imaging should not exclude patients with ischemic heart failure from |
| Q46440950 | Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis? |
| Q37255529 | Dose-dependent cardiac effect of oestrogen replacement in mice post-myocardial infarction |
| Q37490810 | Dose-related neuroprotective versus neurodamaging effects of estrogens in rat cerebral ischemia: a systematic analysis |
| Q44430821 | Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis |
| Q80192444 | Double jeopardy: hormone therapy on trial again |
| Q46734936 | Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms |
| Q53906726 | Drug concentration effect relationship of estradiol from two matrix transdermal delivery systems: Menorest and Climara. |
| Q28165520 | Drug therapy for prevention of recurrent myocardial infarction |
| Q34257829 | Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels |
| Q37079118 | Drugs for cardiovascular disease prevention in women: implications of the AHA Guidelines--2007 Update |
| Q37735189 | Drugs for the treatment of menopausal symptoms. |
| Q34078583 | Drugs used in secondary prevention after myocardial infarction: case presentation |
| Q32061164 | Ductal carcinoma in situ (DCIS) of the breast: diagnostic and therapeutic controversies |
| Q44183854 | Dydrogesterone does not reverse the effects of estradiol on endothelium-dependant vasodilation in postmenopausal women: a randomised clinical trial. |
| Q74163356 | Dyslipidemia |
| Q37582481 | Dyslipidemia in women: etiology and management |
| Q34262624 | Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: implications for therapy |
| Q35116089 | ER-α variants and the cardiovascular effects of hormone replacement therapy |
| Q34935356 | Early menopause predicts angina after myocardial infarction |
| Q37460286 | Early, but not late onset estrogen replacement therapy prevents oxidative stress and metabolic alterations caused by ovariectomy. |
| Q34147730 | Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study |
| Q77375274 | Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective |
| Q73091598 | Effect of 17-beta estradiol on pre-existing atherosclerotic lesions: role of the endothelium |
| Q37487595 | Effect of Half-dose and Standard-dose Conjugated Equine Estrogens Combined with Natural Progesterone or Dydrogesterone on Components of Metabolic Syndrome in Healthy Postmenopausal Women: A Randomized Controlled Trial |
| Q33831845 | Effect of Menstrual Cycle Phases on Plasma Lipid and Lipoprotein Levels in Regularly Menstruating Women |
| Q46535885 | Effect of acute transdermal estrogen administration on basal, mental stress and cold pressor-induced sympathetic responses in postmenopausal women |
| Q34388006 | Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels |
| Q35431110 | Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid |
| Q36016866 | Effect of combined drospirenone with estradiol for hypertensive postmenopausal women: a systemic review and meta-analysis |
| Q44957632 | Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study. |
| Q35092282 | Effect of crude extract of Bombyx mori coccoons in hyperlipidemia and atherosclerosis |
| Q58206750 | Effect of estrogen replacement therapy on corrected thrombolysis in myocardial infarction frame count |
| Q36892322 | Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators |
| Q43751940 | Effect of ethinyl estradiol on the panic response to the panicogenic agent pentagastrin |
| Q54079422 | Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C). |
| Q35642801 | Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy |
| Q44427250 | Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study |
| Q33438267 | Effect of high-dose isoflavones on cognition, quality of life, androgens, and lipoprotein in post-menopausal women |
| Q44274319 | Effect of hormonal replacement therapy on C-reactive protein and cell-adhesion molecules in postmenopausal women |
| Q73141406 | Effect of hormone replacement therapy on age-related increase in carotid artery intima-media thickness in postmenopausal women |
| Q34717132 | Effect of hormone replacement therapy on cardiovascular outcomes: a meta-analysis of randomized controlled trials |
| Q44700353 | Effect of hormone replacement therapy on cardiovascular risk factors in postmenopausal women with diabetes |
| Q44163420 | Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes |
| Q37563372 | Effect of hormone replacement therapy on inflammatory biomarkers. |
| Q43748764 | Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women |
| Q34163992 | Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status |
| Q80406389 | Effect of hormone replacement therapy on postmenopausal endometrial bleeding |
| Q46751367 | Effect of hormone replacement therapy on serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels in post-menopausal women |
| Q78879870 | Effect of hormone replacement therapy on tissue factor activity, C-reactive protein, and the tissue factor pathway inhibitor |
| Q35243693 | Effect of hormone therapy and calcitriol on serum lipid profile in postmenopausal older women: association with estrogen receptor-α genotypes. |
| Q59057086 | Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study |
| Q36732704 | Effect of low-dose oral contraceptives on metabolic risk factors in African-American women |
| Q31817202 | Effect of medroxyprogesterone acetate plus estradiol on endothelium-dependent vasodilation in postmenopausal women |
| Q38846337 | Effect of menopausal hormone therapy on components of the metabolic syndrome. |
| Q44086633 | Effect of methyl testosterone administration on plasma viscosity in postmenopausal women |
| Q45933093 | Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women. |
| Q46912019 | Effect of ovariectomy on cardiac gene expression: inflammation and changes in SOCS gene expression |
| Q43625256 | Effect of physicians opinion on patients' choice of treatment |
| Q40664327 | Effect of postmenopausal hormone replacement on atherosclerosis in femoral arteries |
| Q44234530 | Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study |
| Q73246231 | Effect of postmenopausal hormone therapy on coronary heart disease events after percutaneous transluminal coronary angioplasty |
| Q44088425 | Effect of postmenopausal oestradiol and dydrogesterone therapy on lipoproteins and insulin sensitivity, secretion and elimination in hysterectomised women |
| Q32068104 | Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease |
| Q44470115 | Effect of puberty on coronary arteries from female pigs |
| Q34602093 | Effect of sacral neuromodulation on female sexual function and quality of life: Are they correlated? |
| Q51425653 | Effect of tamoxifen on the coronary vascular reactivity of spontaneously hypertensive female rats. |
| Q44303599 | Effect of tibolone treatment on intima-media thickness and the resistive indices of the carotid arteries |
| Q34686326 | Effect of yoga therapy on physical and psychological quality of life of perimenopausal women in selected coastal areas of Karnataka, India |
| Q33926091 | Effectiveness of compounded bioidentical hormone replacement therapy: an observational cohort study |
| Q44431632 | Effects of Hormone Replacement Therapy on Circulating Docosahexaenoic Acid and Eicosapentaenoic Acid Levels in Postmenopausal Women |
| Q44000451 | Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides |
| Q54084303 | Effects of acute administration of natural progesterone on peripheral vascular responsiveness in healthy postmenopausal women. |
| Q43852476 | Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina |
| Q35178856 | Effects of age and sex on cerebrovascular function in the rat middle cerebral artery |
| Q42651100 | Effects of an herbal medication containing bee products on menopausal symptoms and cardiovascular risk markers: results of a pilot open-uncontrolled trial |
| Q43612137 | Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy |
| Q44445549 | Effects of calcium supplementation on serum lipid levels in postmenopausal women |
| Q73712789 | Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia |
| Q54061634 | Effects of combined sex hormone replacement therapy on small artery biomechanics in pharmacologically ovariectomized rats. |
| Q46417157 | Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women |
| Q44791802 | Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women |
| Q33974473 | Effects of dehydroepiandrosterone (DHEA) on cardiovascular risk factors in older women with frailty characteristics |
| Q45279613 | Effects of estradiol on myocardial global performance index in hypertensive postmenopausal women. |
| Q37273778 | Effects of estradiol on transcriptional profiles in atherosclerotic iliac arteries in ovariectomized cynomolgus macaques |
| Q44445619 | Effects of estradiol, cyproterone acetate, tibolone and raloxifene on uterus and aorta atherosclerosis in oophorectomized cholesterol-fed rabbits. |
| Q46192658 | Effects of estrogen and estrogen-progesteron on serum nitric oxide metabolite concentrations in post-menopausal women |
| Q44621522 | Effects of estrogen and medroxyprogesterone acetate on subpopulations of triglyceride-rich lipoproteins and high-density lipoproteins |
| Q44336721 | Effects of estrogen and opioid blockade on blood pressure reactivity to stress in postmenopausal women |
| Q73055289 | Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women |
| Q36975955 | Effects of estrogen on cerebrovascular function: age-dependent shifts from beneficial to detrimental in small cerebral arteries of the rat |
| Q43230877 | Effects of estrogen plus progesterone on hemodynamic and vascular reactivity in hypertensive postmenopausal women |
| Q35667580 | Effects of estrogen replacement on metabolic factors that influence physical performance in female hypogonadism |
| Q44809174 | Effects of estrogen replacement therapy on natriuretic peptides and blood pressure |
| Q34507109 | Effects of estrogen, an ERα agonist and raloxifene on pressure overload induced cardiac hypertrophy |
| Q37268102 | Effects of gender and sex steroids on ischemic injury |
| Q37225117 | Effects of high-dose isoflavones on metabolic and inflammatory markers in healthy postmenopausal women |
| Q34727136 | Effects of hormone replacement therapy and estrogen receptor modulators on markers of inflammation and coagulation |
| Q44111075 | Effects of hormone replacement therapy on blood platelets |
| Q43593880 | Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). |
| Q34996219 | Effects of hormone replacement therapy on coagulation and fibrinolysis in postmenopausal women |
| Q53676490 | Effects of hormone replacement therapy on plaque stability, inflammation, and fibrinolysis in hypertensive or overweight postmenopausal women. |
| Q73807090 | Effects of hormone replacement therapy on weight, abdominal fat distribution, and lipid levels in Japanese postmenopausal women |
| Q34750495 | Effects of information framing on the intentions of family physicians to prescribe long-term hormone replacement therapy. |
| Q84098205 | Effects of long-term hormone replacement therapy: results from a cohort study |
| Q48458795 | Effects of long-term hormone treatment and of tibolone on monoamines and monoamine metabolites in the brains of ovariectomised, Cynomologous monkeys |
| Q44856184 | Effects of low and high dose oestradiol and dydrogesterone therapy on insulin and lipoprotein metabolism in healthy postmenopausal women |
| Q40632178 | Effects of low dose hormone replacement therapy on markers of inflammation in postmenopausal women |
| Q45929033 | Effects of low-dose continuous combined HRT on vascular function in women with type 2 diabetes. |
| Q51481969 | Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. |
| Q43662494 | Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism |
| Q35101116 | Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism |
| Q47738776 | Effects of oestrogen and Cimicifuga racemosa on the cardiac noradrenaline pathway of ovariectomized rats. |
| Q40516881 | Effects of oestrogen replacement therapy on serum C-reactive protein levels in hysterectomised women |
| Q46799789 | Effects of oestrogen treatment and angiotensin-converting enzyme inhibition on the microvasculature of ovariectomized spontaneously hypertensive rats |
| Q44591322 | Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women |
| Q73186954 | Effects of progestin-estrogen replacement therapy on QT-dispersion in postmenopausal women |
| Q44864424 | Effects of raloxifene and estradiol on hippocampal acetylcholine release and spatial learning in the rat. |
| Q44346425 | Effects of raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopausal women |
| Q44558735 | Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease |
| Q46560125 | Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women |
| Q44406149 | Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects |
| Q37370988 | Effects of short-term administration of estradiol on reperfusion arrhythmias in rats of different ages |
| Q45197318 | Effects of steroid hormones on synaptosomal ectonucleotidase activities from hippocampus and cortex of adult female rats |
| Q46917690 | Effects of tamoxifen on myocardial ischemia-reperfusion injury model in ovariectomized rats |
| Q34627034 | Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study |
| Q36905110 | Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors |
| Q74015185 | Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study |
| Q46905068 | Effects of tibolone on blood flow resistance and intima-media thickness of the carotid arteries: effect of time since menopause |
| Q73928098 | Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy |
| Q94562409 | Efficacy of combined estrogen-progestin hormone contraception therapy for refractory coronary spastic angina in very young women |
| Q34631937 | Efficacy of raloxifene for treatment of menopause: a systematic review |
| Q52036038 | Elderly care. Shifting thinking about memory impairment. |
| Q35044453 | Elevated mean arterial pressure in the ovariectomized rat was normalized by ET(A) receptor antagonist therapy: absence of cardiac hypertrophy and fibrosis |
| Q57802165 | Emerging Research on the Implications of Hormone Replacement Therapy on Coronary Heart Disease |
| Q36383775 | Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women |
| Q37323903 | Endobiogeny: a global approach to systems biology (part 2 of 2) |
| Q77670957 | Endocrine Heart Disease |
| Q37325147 | Endocrine alterations in response to calorie restriction in humans |
| Q44639202 | Endogenous Estrogens Influence Endothelial Function in Young Men |
| Q36353275 | Endogenous androgen deficiency enhances diet-induced hypercholesterolemia and atherosclerosis in low-density lipoprotein receptor-deficient mice |
| Q36339102 | Endogenous sex hormones impact the progression of subclinical atherosclerosis in women during the menopausal transition. |
| Q50967090 | Endometrial response to concurrent treatment with vaginal progesterone and transdermal estradiol. |
| Q49073305 | Endometrial suppression with a new 'frameless' levonorgestrel releasing intrauterine system in perimenopausal and postmenopausal women: a pilot study |
| Q35188942 | Endothelial dysfunction: clinical strategies for treating oxidant stress |
| Q37645668 | Endothelial progenitor cell senescence--is there a role for estrogen? |
| Q34565748 | Epidemiological, endocrine and metabolic features in Turner syndrome. |
| Q36085117 | Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? |
| Q37306273 | Epidemiology of cytokines: the Women On the Move through Activity and Nutrition (WOMAN) Study |
| Q24629433 | Epidemiology of gallbladder disease: cholelithiasis and cancer |
| Q37393211 | Epidemiology of hormone-related venous thromboembolism |
| Q34474087 | Epidemiology of venous thromboembolic disease |
| Q93241704 | Equilin displays similar endothelium-independent vasodilator potential to 17β-estradiol regardless of lower potential to inhibit calcium entry |
| Q37195414 | Escitalopram reduces hot flashes in nondepressed menopausal women: A pilot study |
| Q73224114 | Estradiol 17beta inhibition of LDL oxidation and endothelial cell cytotoxicity is opposed by progestins to different degrees |
| Q34481256 | Estradiol and norgestimate: a review of their combined use as hormone replacement therapy in postmenopausal women |
| Q42493164 | Estradiol decreases IGF-1 and IGF-1 receptor expression in rat aortic smooth muscle cells. Mechanisms for its atheroprotective effects |
| Q43901229 | Estradiol down-regulates MCP-1 expression in human coronary artery endothelial cells |
| Q43692921 | Estradiol enhances endothelium-dependent vasodilation via a nitric oxide pathway |
| Q35141433 | Estradiol exerts neuroprotective actions against ischemic brain injury: insights derived from animal models |
| Q34081355 | Estradiol increases angiotensin II type 1 receptor in hearts of ovariectomized rats |
| Q51782145 | Estradiol increases proteinuria and angiotensin II type 1 receptor in kidneys of rats receiving L-NAME and angiotensin II. |
| Q39477502 | Estradiol inhibits hyaluronic acid synthase 1 expression in human vascular smooth muscle cells |
| Q33518553 | Estradiol stimulates vasodilatory and metabolic pathways in cultured human endothelial cells. |
| Q33592650 | Estradiol-17beta stimulates specific receptor and endogenous nitric oxide-dependent dynamic endothelial protein S-nitrosylation: analysis of endothelial nitrosyl-proteome |
| Q39434008 | Estradiol-delivering vaginal rings for hormone replacement therapy |
| Q34481290 | Estradiol-intranasal: a review of its use in the management of menopause |
| Q30891316 | Estratest and Estratest HS (esterified estrogens and methyltestosterone) therapy: a summary of safety surveillance data, January 1989 to August 2002. |
| Q79091184 | Estrogen Therapy and Risk of Cardiovascular Events Among Women With Type 2 Diabetes |
| Q51534177 | Estrogen Treatment Inhibits Vascular Endothelial Senescence and Asymmetrical Dimethylarginine in Ovariectomized Rabbits |
| Q36721776 | Estrogen action in neuroprotection and brain inflammation. |
| Q39883095 | Estrogen activities and the cellular effects of natural progesterone from wild yam extract in mcf-7 human breast cancer cells |
| Q73143247 | Estrogen administration in patients with chronic heart failure: not ready for prime time |
| Q44410755 | Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size |
| Q35812293 | Estrogen and Cardiovascular Disease: Is Timing Everything? |
| Q52958628 | Estrogen and atherosclerosis. |
| Q74182465 | Estrogen and atherothrombosis |
| Q51648663 | Estrogen and cardiovascular disease: aging and estrogen loss at the heart of the matter? |
| Q48192809 | Estrogen and dementia: it's a long way from the rat to the randomized clinical trial |
| Q35236454 | Estrogen and neuroprotection: from clinical observations to molecular mechanisms. |
| Q36380215 | Estrogen and progestagens differentially modulate vascular proinflammatory factors |
| Q35141438 | Estrogen and selective estrogen receptor modulators: neuroprotection in the Women's Health Initiative era. |
| Q43752524 | Estrogen and testosterone have opposing effects on chronic cardiac remodeling and function in mice with myocardial infarction |
| Q38000962 | Estrogen and the cardiovascular system |
| Q38181814 | Estrogen and the female heart |
| Q34963989 | Estrogen and vascular function |
| Q52716308 | Estrogen and/or Estrogen Receptor α Inhibits BNIP3-Induced Apoptosis and Autophagy in H9c2 Cardiomyoblast Cells. |
| Q51367152 | Estrogen attenuates coupling factor 6-induced salt-sensitive hypertension and cardiac systolic dysfunction in mice. |
| Q35749166 | Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. |
| Q28573241 | Estrogen deficiency decreases ischemic tolerance in the aged rat heart: Roles of PKCdelta, PKCepsilon, Akt, and GSK3beta |
| Q43964443 | Estrogen has opposing effects on vascular reactivity in obese, insulin-resistant male Zucker rats |
| Q36716938 | Estrogen hydroxylation in osteoporosis |
| Q47707895 | Estrogen improves vascular function via peroxisome-proliferator-activated-receptor-γ. |
| Q35162962 | Estrogen in cardiovascular disease during systemic lupus erythematosus |
| Q44103963 | Estrogen increases iNOS expression in the ovine coronary artery |
| Q44120856 | Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice |
| Q74137301 | Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies |
| Q60301627 | Estrogen modulates serotonin effects on vasoconstriction through Src inhibition |
| Q47097266 | Estrogen modulates vascular smooth muscle cell function through downregulation of SIRT1. |
| Q35785178 | Estrogen neuroprotection and the critical period hypothesis |
| Q36368906 | Estrogen plus progestin and colorectal cancer incidence and mortality |
| Q28576245 | Estrogen potentiates constrictor prostanoid function in female rat aorta by upregulation of cyclooxygenase-2 and thromboxane pathway expression |
| Q46529096 | Estrogen potentiates vasopressin-induced contraction of female rat aorta by enhancing cyclooxygenase-2 and thromboxane function |
| Q44387347 | Estrogen promotes microvascular pathology in female stroke-prone spontaneously hypertensive rats |
| Q33773556 | Estrogen protects against increased blood pressure in postpubertal female growth restricted offspring |
| Q45069811 | Estrogen receptor 2 and progesterone receptor gene polymorphisms and lipid levels in women with different hormonal status. |
| Q37610371 | Estrogen receptor actions on vascular biology and inflammation: implications in vascular pathophysiology |
| Q34447516 | Estrogen receptor activation and cardioprotection in ischemia reperfusion injury |
| Q39614971 | Estrogen receptor agonists alleviate cardiac and renal oxidative injury in rats with renovascular hypertension. |
| Q28346553 | Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice |
| Q74625220 | Estrogen receptor-beta and the cardiovascular system |
| Q52609973 | Estrogen receptors do not influence angiogenesis after myocardial infarction. |
| Q36854654 | Estrogen replacement in menopausal women: recent and current prospective studies, the WHI and the KEEPS. |
| Q33579228 | Estrogen replacement restores flow-induced vasodilation in coronary arterioles of aged and ovariectomized rats |
| Q44227851 | Estrogen replacement stimulates fatty acid oxidation and impairs post-ischemic recovery of hearts from ovariectomized female rats |
| Q34557438 | Estrogen replacement therapy and cardioprotection: mechanisms and controversies |
| Q33956373 | Estrogen replacement therapy and the surgeon |
| Q92042117 | Estrogen sulfotransferase in the metabolism of estrogenic drugs and in the pathogenesis of diseases |
| Q36677805 | Estrogen synthesis and signaling pathways during aging: from periphery to brain |
| Q35559544 | Estrogen therapies, lipids, and the heart disease prevention controversy |
| Q34935109 | Estrogen therapy for prevention and treatment of osteoporosis |
| Q43852478 | Estrogen therapy for unstable angina: another bump for the bandwagon |
| Q44509593 | Estrogen therapy induces collateral and microvascular remodeling |
| Q36948209 | Estrogen therapy, independent of timing, improves cardiac structure and function in oophorectomized mRen2.Lewis rats |
| Q28383144 | Estrogen, aging and the cardiovascular system |
| Q35070227 | Estrogen, hormonal replacement therapy and cardiovascular disease |
| Q46698837 | Estrogen, nitric oxide, and hypertension differentially modulate agonist-induced contractile responses in female transgenic (mRen2)27 hypertensive rats |
| Q34375771 | Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease |
| Q37286107 | Estrogen-eluting stents |
| Q44161865 | Estrogen-eluting, phosphorylcholine-coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model |
| Q36835892 | Estrogen-induced improvement in coronary flow responses during atrial pacing in relation to endothelin-1 levels in postmenopausal women without coronary disease |
| Q32054926 | Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women |
| Q43276874 | Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? |
| Q53203297 | Estrogenic Impact on Cardiac Ischemic/Reperfusion Injury. |
| Q42480099 | Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets |
| Q35540815 | Estrogens ,homocysteine ,vasodilatation and menopause: basic mechanisms ,interactions and clinical implications |
| Q80815527 | Estrogens and Stroke: Use of Oral Contraceptives and Postmenopausal Use of Estrogen: Current Recommendations |
| Q34449454 | Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative |
| Q34505835 | Estrogens and lipids. Can HRT designer estrogens, and phytoestrogens reduce cardiovascular risk markers after menopause? |
| Q34132661 | Estrogens and women's health: interrelation of coronary heart disease, breast cancer and osteoporosis |
| Q73536363 | Estrogens, lipids and cardiovascular disease: no easy answers |
| Q35181580 | Estrogens, progestogens and thrombosis |
| Q35131953 | Estrogens: protective or risk factors in brain function? |
| Q33778878 | Ethnic differences in hormone replacement prescribing patterns |
| Q31148198 | Evaluating uses of data mining techniques in propensity score estimation: a simulation study |
| Q39531253 | Evaluation of hormone replacement therapy use by the sales figures |
| Q73156908 | Evidence against a role of physiological concentrations of estrogen in post-myocardial infarction remodeling |
| Q34152308 | Evidence from randomised trials on the long-term effects of hormone replacement therapy |
| Q28579839 | Evidence to implicate early modulation of interleukin-1beta expression in the neuroprotection afforded by 17beta-estradiol in male rats undergone transient middle cerebral artery occlusion |
| Q43092322 | Evidence-based common sense? |
| Q36052183 | Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club |
| Q35197119 | Evidence-based management of dyslipidemias in women |
| Q80443430 | Evidence-based medicine and hormone replacement therapy |
| Q84007797 | Evidence-based medicine should be practiced for primary prevention and secondary prevention of cardiovascular disease |
| Q48709694 | Exercise and menopause: a time for positive changes |
| Q35811225 | Exercise beyond menopause: Dos and Don'ts |
| Q24234440 | Exercise for vasomotor menopausal symptoms |
| Q24243116 | Exercise for vasomotor menopausal symptoms |
| Q24245931 | Exercise for vasomotor menopausal symptoms |
| Q24187786 | Exercise for vasomotor menopausal symptoms |
| Q36082036 | Exercise participation, body mass index, and health-related quality of life in women of menopausal age. |
| Q34227082 | Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy |
| Q52087334 | Experiential learning influences residents knowledge about hormone replacement therapy. |
| Q33572292 | Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease |
| Q53677688 | Explanatory models are needed to integrate RCT and observational data with the patient's unique biology. |
| Q33232047 | Exploring the continuum: medical information to effective clinical practice. Paper I: the translation of knowledge into clinical practice |
| Q36792134 | Exposures to synthetic estrogens at different times during the life, and their effect on breast cancer risk |
| Q77355097 | Expression of estrogen receptor sub-types alpha and beta in acute and chronic cardiac allograft vasculopathy |
| Q35561175 | Extra-Nuclear Signaling Pathway Involved in Progesterone-Induced Up-Regulations of p21cip1 and p27kip1 in Male Rat Aortic Smooth Muscle Cells |
| Q35579158 | Factor V Leiden and Venous Thromboembolism: Risk Associated With Hormone Replacement Therapy |
| Q81155009 | Factor VIIa as a predictor of cardiac events following myocardial infarction in women |
| Q37416367 | Failure to consider the menstrual cycle phase may cause misinterpretation of clinical and research findings of cardiometabolic biomarkers in premenopausal women |
| Q28186835 | Familiar drugs may prevent cancer |
| Q44591325 | Fatty acid composition of serum phospholipid of premenopausal women and postmenopausal women receiving and not receiving hormone replacement therapy |
| Q46703024 | Female sex hormones decrease constitutive endothelin-1 release via endothelial sigma-1/cocaine receptors: an action independent of the steroid hormone receptors |
| Q34027246 | Fibrinogen and coronary risk |
| Q56673117 | Five Decades of Hormone Therapy Research: The Long, the Short, and the Inconclusive |
| Q40566668 | Fracture and the risk of coronary events in women with heart disease |
| Q47757313 | From Nonclinical Research to Clinical Trials and Patient-registries: Challenges and Opportunities in Biomedical Research |
| Q24609289 | Functional limitations, socioeconomic status, and all-cause mortality in moderate alcohol drinkers |
| Q85942860 | Fundamentals of knowledge translation |
| Q49929077 | GPCRS IN CONTEXT: SEXUAL DIMORPHISM IN THE CARDIOVASCULAR SYSTEM. |
| Q33835934 | GPER/GPR30 and Regulation of Vascular Tone and Blood Pressure. |
| Q35186618 | GPR30 decreases cardiac chymase/angiotensin II by inhibiting local mast cell number |
| Q30316948 | GRADE guidelines 15: going from evidence to recommendation - determinants of a recommendation's direction and strength |
| Q27860753 | GRADE: an emerging consensus on rating quality of evidence and strength of recommendations |
| Q35561234 | Gender and cardiac surgery |
| Q47571604 | Gender and cardiovascular disease: are sex-biased microRNA networks a driving force behind heart failure with preserved ejection fraction in women? |
| Q36653383 | Gender and gallstone disease |
| Q38172048 | Gender and outcomes of carotid artery interventions |
| Q37209917 | Gender and sex hormones in multiple sclerosis pathology and therapy. |
| Q33716546 | Gender and vascular reactivity |
| Q34736587 | Gender balance in cardiovascular research: importance to women's health |
| Q38257023 | Gender difference in the pathophysiology and treatment of glaucoma. |
| Q44183021 | Gender differences in cardiac ACE expression are normalized in androgen-deprived male mice |
| Q37527487 | Gender differences in cardiac ischemic injury and protection--experimental aspects. |
| Q37427243 | Gender differences in coronary artery disease: review of diagnostic challenges and current treatment |
| Q26998447 | Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase |
| Q78818609 | Gender differences in post-infarction hypertrophy in end-stage failing hearts |
| Q43672165 | Gender differences in the cardiovascular effect of sex hormones |
| Q44417032 | Gender differences in the expression of heat shock proteins: the effect of estrogen. |
| Q35050911 | Gender differences in the regulation of vascular tone |
| Q43646762 | Gender differences in vascular compliance in young, healthy subjects assessed by pulse contour analysis |
| Q33771819 | Gender dimorphisms in progenitor and stem cell function in cardiovascular disease |
| Q35788968 | Gender gap in acute coronary heart disease: Myth or reality? |
| Q46744259 | Gender specific generation of nitroxyl (HNO) from rat endothelium |
| Q35095785 | Gender specific patterns of age-related decline in aortic stiffness: a cardiovascular magnetic resonance study including normal ranges |
| Q35109844 | Gender, hyperlipidemia, and coronary artery disease |
| Q38501418 | Gender-Related Differences in Atherosclerosis. |
| Q28199679 | Gender-specific care of the patient with diabetes: review and recommendations |
| Q35638586 | Genetics and tailored therapy in cardiovascular disease |
| Q35096844 | Genistein Induces Estrogen-Like Effects in Ovariectomized Rats but Fails to Increase Cardiac GLUT4 and Oxidative Stress |
| Q43969410 | Genistein and exercise do not improve cardiovascular risk factors in the ovariectomized rat. |
| Q92475983 | Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis |
| Q37474877 | Glutathione peroxidase deficiency exacerbates ischemia-reperfusion injury in male but not female myocardium: insights into antioxidant compensatory mechanisms |
| Q34152777 | Glycaemic control and hormone replacement therapy: implications of the Postmenopausal Estrogen/Progestogen Intervention (PEPI) study |
| Q43786652 | Glycaemic control and plasma lipoproteins in menopausal women with Type 2 diabetes treated with oral and transdermal combined hormone replacement therapy |
| Q24562409 | Grading quality of evidence and strength of recommendations |
| Q35197876 | Growth hormone and cardiovascular risk markers |
| Q37379541 | Growth hormone and sex steroid effects on serum glucose, insulin, and lipid concentrations in healthy older women and men. |
| Q37396676 | Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone |
| Q84618098 | Guidelines for Diagnosis and Treatment of Patients With Vasospastic Angina (Coronary Spastic Angina) (JCS 2008) - Digest Version - |
| Q34299778 | Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. |
| Q35903489 | Guidelines for menopausal hormone therapy: Recommendations of the Polish Menopause and Andropause Society - state of knowledge as of December 2013. |
| Q35062386 | HDL in risk prediction and its direct and indirect involvement in atherogenesis |
| Q35123607 | HMG CoA reductase inhibitors and the skeleton: a comprehensive review |
| Q57910275 | HRT and heart disease: Dr Jekyll or Mrs Hyde? |
| Q34181916 | HRT and its impact on the menopause, osteoporosis and breast cancer |
| Q42720980 | HRT and venous thromboembolism: more evidence of a link. |
| Q44363829 | HRT does not improve urinary albumin excretion in postmenopausal diabetic women |
| Q37847568 | HRT in difficult circumstances: are there any absolute contraindications? |
| Q34407513 | HRT in women with diabetes--review of the effects on glucose and lipid metabolism |
| Q34044754 | HRT to prevent cardiovascular disease. What studies show, how to advise patients |
| Q82443582 | HRT, women and heart disease: facts about prevention |
| Q35563932 | HT and CVD prevention. from myth to reality |
| Q44183857 | Haemostatic risk factors in healthy postmenopausal women taking hormone replacement therapy |
| Q39404949 | Has the prevalence of cholesterol gallstones increased in Korea? A preliminary single-center experience |
| Q44688822 | Health behaviors, body composition, and coronary heart disease risk in women with multiple sclerosis |
| Q35411292 | Health status of users of hormone replacement therapy by hysterectomy status in Western Australia. |
| Q36841069 | Health-related quality of life following coronary artery bypass graft surgery in post-menopausal women |
| Q34799001 | Healthy user and related biases in observational studies of preventive interventions: a primer for physicians |
| Q53082495 | Healthy users, healthy adherers, and healthy behaviors? |
| Q33986414 | Heart disease in women |
| Q33949725 | Heart disease in women. Gender-specific statistics and prevention strategies for a population at risk |
| Q73185359 | Heart disease linked to oestrogen-receptor gene methylation |
| Q83569411 | Heart failure in women |
| Q39573300 | Heart rate variability under resting conditions in postmenopausal and young women |
| Q38823562 | Heme Oxygenases in Cardiovascular Health and Disease |
| Q44459477 | Hemodialysis and estrogen levels in postmenopausal (HELP) patients: The multicenter HELP study |
| Q46976029 | Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep |
| Q34548827 | Hemostatic and inflammatory markers as risk factors for coronary disease in the elderly |
| Q39336336 | High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol |
| Q34123188 | High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport |
| Q36366159 | High level of plasma estradiol as a new predictor of ischemic arterial disease in older postmenopausal women: the three-city cohort study. |
| Q34973446 | High sensitivity C-reactive protein: an emerging role in cardiovascular risk assessment |
| Q35777408 | High-density lipoproteins: multifunctional vanguards of the cardiovascular system |
| Q40728614 | High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy |
| Q34314897 | Hip fracture prevention: cost-effective strategies |
| Q33721739 | History of hot flashes and aortic calcification among postmenopausal women |
| Q34716812 | Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)inaemia |
| Q24239981 | Homocysteine lowering interventions for preventing cardiovascular events |
| Q35840036 | Homocysteine, B-vitamin supplementation, and stroke prevention: from observational to interventional trials |
| Q35536136 | Hormonal and nutritional effects on cardiovascular risk markers in young women |
| Q37980611 | Hormonal effects on blood vessels |
| Q33887863 | Hormonal replacement regimens and bleeding |
| Q34821414 | Hormonal replacement therapy |
| Q44620741 | Hormonal replacement therapy and cardiovascular risk: contra-indication or non-indication? |
| Q39353579 | Hormonal therapy of menopause: 2004 position of the Department of Female Endocrinology and Andrology of the Brazilian Society of Endocrinology and Metabolism |
| Q39396170 | Hormone Replacement Therapy for Primary and Secondary Prevention of Heart Disease |
| Q57466987 | Hormone Replacement Therapy: Would it be Possible to Replicate a Functional Ovary? |
| Q82194744 | Hormone in the hot seat |
| Q34707898 | Hormone replacement and the prevention of cardiovascular disease |
| Q34013219 | Hormone replacement for the new millennium |
| Q33695737 | Hormone replacement therapy |
| Q74490958 | Hormone replacement therapy |
| Q34522168 | Hormone replacement therapy (estrogen and progesterone): is it necessary for heart disease prevention? |
| Q42532733 | Hormone replacement therapy after the menopause--where are we now? |
| Q73572665 | Hormone replacement therapy after treatment for breast cancer: physicians' attitudes towards randomized trials |
| Q73235133 | Hormone replacement therapy and C-reactive protein |
| Q43795711 | Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial |
| Q43707474 | Hormone replacement therapy and breast cancer: revisiting the issues. |
| Q74662503 | Hormone replacement therapy and cardiovascular disease |
| Q73830376 | Hormone replacement therapy and cardiovascular disease: an evidence based approach |
| Q35918730 | Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease |
| Q35757554 | Hormone replacement therapy and cardiovascular disease: lessons from a monkey model of postmenopausal women |
| Q34011174 | Hormone replacement therapy and cardiovascular risk |
| Q73707134 | Hormone replacement therapy and cardiovascular risk: do abnormalities of coagulation and fibrinolysis matter? |
| Q33843646 | Hormone replacement therapy and coronary heart disease. A new debate |
| Q73226853 | Hormone replacement therapy and distensibility of carotid arteries in postmenopausal women: a randomized, controlled trial |
| Q43813819 | Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women |
| Q32028226 | Hormone replacement therapy and fractures in older adults |
| Q42331789 | Hormone replacement therapy and heart disease: the remains of the oestrogen hypothesis |
| Q78044450 | Hormone replacement therapy and heart-rate variability |
| Q44472887 | Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study |
| Q35182014 | Hormone replacement therapy and menopause: a review of randomized, double-blind, placebo-controlled trials |
| Q35981132 | Hormone replacement therapy and peripheral vascular disease in women |
| Q35080663 | Hormone replacement therapy and primary prevention: alas, again... |
| Q36144161 | Hormone replacement therapy and risk of acute myocardial infarction : a review of the literature. |
| Q73389727 | Hormone replacement therapy and risk of acute myocardial infarction in postmenopausal women with diabetes mellitus |
| Q34532001 | Hormone replacement therapy and risk of new-onset atrial fibrillation after myocardial infarction--a nationwide cohort study |
| Q33222171 | Hormone replacement therapy and secondary cardiovascular prevention: a meta-analysis of randomized trials |
| Q34254656 | Hormone replacement therapy and stroke: risk, protection or no effect? |
| Q34935126 | Hormone replacement therapy and surveillance considerations |
| Q22252375 | Hormone replacement therapy and the association with coronary heart disease and overall mortality: Clinical application of the timing hypothesis |
| Q44502744 | Hormone replacement therapy and the risk of breast cancer: assessment of therapy acceptance in a cohort of previously treated breast cancer patients |
| Q81975856 | Hormone replacement therapy and thrombotic risk: beauty is only skin deep |
| Q34491410 | Hormone replacement therapy at the threshold of 21st century |
| Q92199099 | Hormone replacement therapy attenuates hearing loss: Mechanisms involving estrogen and the IGF-1 pathway |
| Q36620341 | Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients |
| Q45245870 | Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens. |
| Q51561050 | Hormone replacement therapy enhances postprandial lipid metabolism in postmenopausal women. |
| Q35198540 | Hormone replacement therapy for postmenopausal osteoporosis |
| Q39417734 | Hormone replacement therapy for postmenopausal women with diabetes |
| Q24244146 | Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women |
| Q34327242 | Hormone replacement therapy for prevention of coronary heart disease: current evidence |
| Q33554786 | Hormone replacement therapy for the primary prevention of chronic diseases: recommendation statement from the Canadian Task Force on Preventive Health Care |
| Q26471218 | Hormone replacement therapy for women previously treated for endometrial cancer |
| Q24234201 | Hormone replacement therapy for women previously treated for endometrial cancer |
| Q51834819 | Hormone replacement therapy improves arterial stiffness in normotensive postmenopausal women. |
| Q36739263 | Hormone replacement therapy in breast cancer survivors |
| Q37862831 | Hormone replacement therapy in gynecologic cancer survivors: why not? |
| Q42625420 | Hormone replacement therapy in healthy postmenopausal women. Effects on intraplatelet cyclic guanosine monophosphate, plasma endothelin-1 and neopterin |
| Q42646583 | Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors |
| Q43561959 | Hormone replacement therapy in ischemic heart disease prevention in women. Arguments in favor |
| Q39207067 | Hormone replacement therapy in menopause |
| Q73069623 | Hormone replacement therapy in perimenopausal women and 2-year change of carotid intima-media thickness |
| Q77414479 | Hormone replacement therapy in postmenopausal women and cardiovascular risk |
| Q34734554 | Hormone replacement therapy in postmenopausal women and its effects on plasma lipid levels |
| Q62899568 | Hormone replacement therapy in postmenopausal women protects against smoking-induced changes in vascular structure and function |
| Q34145809 | Hormone replacement therapy in postmenopausal women with diabetes mellitus: a risk-benefit assessment |
| Q80503511 | Hormone replacement therapy in systemic lupus erythematosus |
| Q34107469 | Hormone replacement therapy in the prevention and treatment of atherosclerosis |
| Q35081294 | Hormone replacement therapy in women with a history of breast cancer |
| Q35966781 | Hormone replacement therapy in women with spinal cord injury - a survey with literature review |
| Q51651321 | Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease. |
| Q44304778 | Hormone replacement therapy increases renal kallikrein excretion in healthy postmenopausal women |
| Q46077959 | Hormone replacement therapy is associated with improved survival in women with advanced heart failure |
| Q34315109 | Hormone replacement therapy is safe in women undergoing coronary artery bypass grafting |
| Q34041348 | Hormone replacement therapy should be administered as secondary prevention of coronary artery disease |
| Q34041341 | Hormone replacement therapy should not be used as secondary prevention of coronary heart disease |
| Q43812305 | Hormone replacement therapy to improve left ventricular diastolic functions in healthy postmenopausal women |
| Q43873735 | Hormone replacement therapy trials: an update |
| Q39539713 | Hormone replacement therapy use in urban older women attending meal sites: associations with sociodemographic and health characteristics and use of preventive services |
| Q44000447 | Hormone replacement therapy with estradiol valerate and cyproterone acetate: effects on endothelium-dependent vasodilatation and arterial wall compliance |
| Q44660785 | Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women |
| Q35419972 | Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives |
| Q36577501 | Hormone replacement therapy. Does it actually help with heart disease? |
| Q34032418 | Hormone replacement therapy: a survey of Ontario physicians' prescribing practices. |
| Q33902183 | Hormone replacement therapy: a time for pause |
| Q36240364 | Hormone replacement therapy: an update |
| Q34256116 | Hormone replacement therapy: clarifying the picture |
| Q36372415 | Hormone replacement therapy: dilemmas in 2002. |
| Q52925012 | Hormone replacement therapy: discrepancies between evidence and recommendations. |
| Q74148235 | Hormone replacement therapy: knowledge, attitudes, self-reported use - and sales figures in Nordic women |
| Q34995241 | Hormone replacement therapy: optimising the dose and route of administration |
| Q36203259 | Hormone replacement therapy: review, update, and remaining questions after the Women's Health Initiative Study |
| Q78670234 | Hormone replacement therapy: short-term versus long-term use |
| Q34455239 | Hormone replacement therapy: the benefits in tailoring the regimen and dose |
| Q33731351 | Hormone replacement therapy: where are we now? |
| Q35647802 | Hormone therapies and vascular outcomes: who is at risk? |
| Q37813184 | Hormone therapies and venous thromboembolism: where are we now? |
| Q36686804 | Hormone therapy and cardiovascular disease |
| Q37608577 | Hormone therapy and cardiovascular risk markers and disease: focus on progestagens |
| Q77753116 | Hormone therapy and heart disease |
| Q34417085 | Hormone therapy and heart disease after the menopause |
| Q45107268 | Hormone therapy and mortality during a 14-year follow-up of 14 324 Norwegian women |
| Q35751419 | Hormone therapy and risk of cardiovascular outcomes and mortality in women treated with statins |
| Q34935018 | Hormone therapy and the cardiovascular system |
| Q46580577 | Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women |
| Q47551752 | Hormone therapy and urine protein excretion: a multiracial cohort study, systematic review, and meta-analysis |
| Q35134618 | Hormone therapy and venous thromboembolism |
| Q24187326 | Hormone therapy for preventing cardiovascular disease in post-menopausal women |
| Q24197712 | Hormone therapy for preventing cardiovascular disease in post-menopausal women |
| Q37867308 | Hormone therapy for the management of menopausal symptoms: pharmacotherapy update |
| Q46834697 | Hormone therapy in menopause: when not to use |
| Q36459544 | Hormone therapy in the WHI era. |
| Q46265323 | Hormone therapy in women after heart transplantation |
| Q41463208 | Hormone therapy might be underutilized in women with early menopause |
| Q46060638 | Hormone therapy modulates ET(A) mRNA expression in the aorta of ovariectomised New Zealand White rabbits |
| Q28730966 | Hormone treatment, estrogen receptor polymorphisms and mortality: a prospective cohort study |
| Q37214255 | Hormone use and risk for lung cancer: a pooled analysis from the International Lung Cancer Consortium (ILCCO) |
| Q34593579 | Hormone-dependent aging problems in women |
| Q37292711 | Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women |
| Q34688660 | Hormone-replacement therapy and breast cancer |
| Q38975101 | Hormone-replacement therapy: current thinking |
| Q34267973 | Hormones after menopause? |
| Q35948682 | Hormones and coronary atherosclerosis in women |
| Q30988720 | Hormones and endometrial cancer--new data from the Million Women Study |
| Q34675309 | Hormones and heart disease: what we thought, what we have learned, what we still need to know |
| Q36362593 | Hormones and menopause: pro. |
| Q35852845 | Hormones and pregnancy: thromboembolic risks for women |
| Q94177919 | Hormones for coronary disease |
| Q78724442 | Hormones for coronary disease-full circle |
| Q35979363 | Hormones, menopause, and heart disease: making sense of the Women's Health Initiative |
| Q56627217 | Hormontherapie mit Östrogenen und Gestagenen in der Peri- und Postmenopause |
| Q35216824 | Hot flashes in breast cancer survivors |
| Q35024871 | Hot flushes |
| Q43073625 | Hot flushes and biochemical markers for cardiovascular disease: a randomized trial on hormone therapy |
| Q33797836 | Hot flushes, coronary heart disease, and hormone therapy in postmenopausal women |
| Q34637549 | How often are ineffective interventions still used in clinical practice? A cross-sectional survey of 6,272 clinicians in China |
| Q36416760 | How the Women's Health Initiative (WHI) influenced physicians' practice and attitudes |
| Q46755958 | How to stay heart healthy in 2011: considerations for the primary prevention of cardiovascular disease in women |
| Q35045916 | Hyper-reactivity of cerebral arteries from ovariectomized rats: therapeutic benefit of tamoxifen |
| Q46141799 | Hyperglycemia and loss of ovarian hormones mediate atheroma formation through endothelial layer disruption and increased permeability |
| Q33986367 | Hyperlipidemia |
| Q45832764 | Hyperlipidemia: Part 2. Pharmacologic management |
| Q26866656 | Hypertension: what's sex got to do with it? |
| Q36112946 | Hypertrophy in the female heart |
| Q44307928 | Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study |
| Q94597199 | Hypothalamic estrogen receptor alpha establishes a sexually dimorphic regulatory node of energy expenditure |
| Q58575874 | Identification of Menopausal and Reproductive Risk Factors for Microscopic Colitis—Results From the Nurses’ Health Study |
| Q34049014 | Identifying and Avoiding Bias in Research |
| Q24804138 | Identifying patient preferences for communicating risk estimates: a descriptive pilot study |
| Q73559562 | Immune effects of hormone replacement therapy in post-menopausal women |
| Q35580606 | Impact of age and sex on sudden cardiovascular death following myocardial infarction |
| Q35233878 | Impact of aging vs. estrogen loss on cardiac gene expression: estrogen replacement and inflammation |
| Q37316399 | Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases |
| Q73355160 | Impact of hormonal deficit and cardiovascular risk factors on life expectancy in hypopituitarism |
| Q44855691 | Impact of long-term hormone replacement therapy on in vivo and in vitro markers of lipid oxidation |
| Q37538095 | Impact of ovarian function on cardiovascular health in women: focus on hypertension |
| Q34712250 | Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease |
| Q35546640 | Implications of Gender Difference in Coronary Calcification as Assessed by CT Coronary Angiography |
| Q42451919 | Improvement of Endothelial Dysfunction by Selective Estrogen Receptor-α Stimulation in Ovariectomized SHR |
| Q73893753 | In support of HRT |
| Q42615899 | Incidence and early prognosis of aneurysmal subarachnoid hemorrhage in Kumamoto Prefecture, Japan |
| Q72991859 | Incidence of acute myocardial infarction and cause-specific mortality after transurethral treatments of prostatic hypertrophy |
| Q31082876 | Increased cardiovascular and renal risk is associated with low nephron endowment in aged females: an ovine model of fetal unilateral nephrectomy |
| Q89501309 | Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities |
| Q44855702 | Increased levels of superoxide in brains from old female rats |
| Q36027022 | Increased longevity in older users of postmenopausal estrogen therapy: the Leisure World Cohort Study |
| Q57788471 | Increased longevity in older users of postmenopausal estrogen therapy: the Leisure World Cohort Study |
| Q21132351 | Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men |
| Q77853741 | Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease |
| Q35159922 | Inducible nitric oxide synthase provides protection against injury-induced thrombosis in female mice |
| Q37304927 | Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy |
| Q37178618 | Influence of aging and menopause on lipids and lipoproteins in women |
| Q53593694 | Influence of menopausal status and use of hormone replacement therapy on radiation dose from mammography in routine breast screening. |
| Q33721061 | Influence of sex hormones and phytoestrogens on heart disease in men and women |
| Q44445540 | Influence of the menstrual cycle on the timing of acute coronary events in premenopausal women |
| Q57664322 | Influências da reposição de estrógenos e progestágenos na ação do hormônio de crescimento em mulheres com hipopituitarismo |
| Q33456205 | Informing women about hormone replacement therapy: the consensus conference statement |
| Q74194564 | Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up |
| Q36404619 | Inquiring minds: women's approaches to evaluating complementary and alternative therapies for menopausal symptoms. |
| Q30473662 | Insulin resistance as a risk factor for gallbladder stone formation in Korean postmenopausal women |
| Q46209142 | Interaction of estrogen and tumor necrosis factor alpha in endothelial cell migration and early stage of angiogenesis |
| Q30245459 | Interpretation of the evidence for the efficacy and safety of statin therapy |
| Q34575187 | Intrauterine application of progestins in hormone replacement therapy: a review |
| Q38212588 | Intrawound vancomycin to prevent infections after spine surgery: a systematic review and meta-analysis |
| Q34707872 | Introduction: the role of hormone replacement therapy in prevention and treatment of cardiovascular disease in postmenopausal women |
| Q34177765 | Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents |
| Q34444907 | Invited review: Pharmacogenetics of estrogen replacement therapy |
| Q46535877 | Is "cardiovascular protection" by estrogens due to inhibition of the sympathetic nervous system? |
| Q44592446 | Is There a Role for Menopausal Hormone Therapy (MHT) for Cardiovascular Disease Prevention in Select Postmenopausal Women? |
| Q34077942 | Is hypercholesterolemia a risk factor and should it be treated in the elderly? |
| Q43891179 | Is postmenopausal hormone replacement therapy suitable after a cardio- or cerebrovascular event? |
| Q37440373 | Is progesterone a candidate neuroprotective factor for treatment following ischemic stroke? |
| Q30839166 | Is screening for breast cancer with mammography justifiable? |
| Q81002469 | Is the WHI relevant to HRT started in the perimenopause? |
| Q34935164 | Is there a menopausal medicine? The past the present and the future |
| Q34682870 | Ischaemic heart disease in women: are there sex differences in pathophysiology and risk factors? Position paper from the working group on coronary pathophysiology and microcirculation of the European Society of Cardiology |
| Q73236735 | Ischemic Heart Disease |
| Q22251459 | Ischemic heart disease in women: a focus on risk factors |
| Q33183833 | Isoflavone supplementation and endothelial function in menopausal women |
| Q34714748 | Issues of hormone replacement therapy and cardiovascular disease for elderly women |
| Q36970351 | Italian position statement on hormone replacement therapy following the National Conference on Menopause and Hormone Replacement Therapy, Villa Tuscolana, Frascati (Rome), May 8-9, 2007. |
| Q58362346 | Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017 |
| Q37196548 | Joint position statement of the Polish Cardiologic Society, the Polish Gynaecological Society and the Polish Menopause and Andropause Society on the effect of postmenopausal hormone replacement therapy on the cardiovascular system. |
| Q50568916 | Knowledge, attitudes and management strategies in Scandinavia concerning hormone replacement therapy: a comparison between gynecologists in Denmark, Norway and Sweden. |
| Q34031435 | Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: a systematic review and meta-synthesis |
| Q44111506 | Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestins |
| Q74304946 | Large-scale hormone replacement therapy and life expectancy: results from an international comparison among European and North American populations |
| Q37861982 | Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis. |
| Q90613954 | Late Onset of Estrogen Therapy Impairs Carotid Function of Senescent Females in Association with Altered Prostanoid Balance and Upregulation of the Variant ERα36 |
| Q79267929 | Left ventricular hypertrophy: a surrogate end point or correlate of cardiovascular events in kidney disease? |
| Q34319242 | Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. |
| Q52804643 | Life prevalence of hormone replacement therapy and profile of users have not changed among women with self-reported menopause in the last two decades in Porto, Portugal. |
| Q34326367 | Lifestyle and demographic factors in relation to vasomotor symptoms: baseline results from the Study of Women's Health Across the Nation |
| Q38536883 | Limitations in conduct and reporting of cochrane reviews rarely inhibit the determination of the validity of evidence for clinical decision-making |
| Q37811982 | Lipid Effects of Endocrine Medications |
| Q37223211 | Lipid biomarkers, hormone therapy and the risk of venous thromboembolism in women |
| Q44642214 | Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study (HERS). |
| Q35866701 | Lipid management and the elderly |
| Q44454497 | Lipid profiles and endothelial function with low-dose hormone replacement therapy in postmenopausal women at risk for coronary artery disease: a randomized trial |
| Q34457386 | Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program |
| Q35557793 | Lipid-lowering agents and the risk of hip fracture in a Medicaid population |
| Q28354365 | Lipid-lowering update 2001. Aggressive new goals |
| Q36331015 | Lipids and stroke: the opportunity of lipid-lowering treatment |
| Q34990631 | Lipoprotein abnormalities related to women's health |
| Q37240036 | Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials |
| Q33825076 | Lipoprotein subclasses and endogenous sex hormones in women at midlife |
| Q24629580 | Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events |
| Q35543364 | Local delivery of a PKCε-activating peptide limits ischemia reperfusion injury in the aged female rat heart |
| Q24241279 | Long term hormone therapy for perimenopausal and postmenopausal women |
| Q24246577 | Long term hormone therapy for perimenopausal and postmenopausal women |
| Q24201974 | Long term hormone therapy for perimenopausal and postmenopausal women |
| Q78840719 | Long term-effects of hormone replacement therapy |
| Q39175806 | Long-Term Hormone Replacement Therapy Is Associated with Low Coronary Artery Calcium Levels in a Cohort of Older Women: The Age, Gene/Environment Susceptibility-Reykjavik Study |
| Q44194671 | Long-term (three years) effect of estrogen replacement therapy on major adverse cardiac events in postmenopausal women after intracoronary stenting |
| Q43852452 | Long-term effects of continuous oral and transdermal estrogen replacement therapy on sex hormone binding globulin and free testosterone levels |
| Q78840714 | Long-term effects of hormone replacement therapy |
| Q44643694 | Long-term estradiol treatment improves VIP-mediated vasodilation in atherosclerotic proximal coronary arteries |
| Q41727278 | Long-term estrogen replacement therapy is associated with improved exercise capacity in postmenopausal women without known coronary artery disease |
| Q30238978 | Long-term hormone therapy for perimenopausal and postmenopausal women |
| Q39934818 | Long-term prevention with hormone-replacement therapy after the menopause: which women should be targeted? |
| Q51355481 | Long-term prospective study of the influence of estrone levels on events in postmenopausal women with or at high risk for coronary artery disease. |
| Q34272056 | Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update |
| Q34249097 | Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy |
| Q35203793 | Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment |
| Q36053335 | Low use of long-term hormone replacement therapy in Denmark |
| Q46259264 | Low- and standard-estrogen dosage in oral therapy: dose-dependent effects on insulin and lipid metabolism in healthy postmenopausal women. |
| Q42723918 | Low-density lipoprotein cholesterol reduction and prevention of cardiovascular disease |
| Q33652873 | Low-potency oestrogen and risk of endometrial cancer: a case-control study |
| Q51809296 | Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. |
| Q73712815 | Lp(a) and lipids in adult Turner's syndrome: impact of treatment with 17beta-estradiol and norethisterone |
| Q34649417 | Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women |
| Q44880342 | Making a decision about ERT/HRT. Evidence to consider in initiating and continuing protective therapy |
| Q36059327 | Making a decision about hormone replacement therapy. A randomized controlled trial |
| Q33813785 | Making decisions about hormone replacement therapy |
| Q46071955 | Management After Myocardial Infarction |
| Q55539705 | Management of Medical Morbidities and Risk Factors Before Surgery: Smoking, Diabetes, and Other Complicating Factors. |
| Q35919125 | Management of age-related osteoporosis and prevention of associated fractures |
| Q37020195 | Management of cardiovascular risk in the perimenopausal women: a consensus statement of European cardiologists and gynecologists |
| Q73743833 | Management of coronary artery disease |
| Q34722828 | Management of dyslipidemia in women in the post-hormone therapy era. |
| Q35692886 | Management of dyslipidemias in the age of statins |
| Q34655133 | Management of hypercholesterolaemia in postmenopausal women |
| Q33843611 | Management of hypercholesterolemia |
| Q38720569 | Management of menopausal symptoms in women with gynecologic cancers |
| Q35019670 | Management of the menopause in cancer survivors |
| Q36417952 | Managing Hypertension in Patients with CKD: A Marathon, Not a SPRINT. |
| Q33790720 | Managing dyslipidemia in older adults |
| Q36577705 | Managing elderly people's osteoporosis. Why? Who? How? |
| Q35117241 | Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan |
| Q22241929 | Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association |
| Q38086244 | Matters of the heart: cardiovascular disease in U.S. women. |
| Q92000906 | Maximal dose-response of vitamin-K2 (menaquinone-4) on undercarboxylated osteocalcin in women with osteoporosis |
| Q34435617 | Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation |
| Q44588472 | Mechanisms of 17beta-estradiol on the production of ET-1 in ovariectomized rats |
| Q51821384 | Mechanisms of thrombosis related to hormone therapy. |
| Q77682081 | Medical and psychological aspects of hormone replacement therapy in postmenopausal women: points of view from a cardiologist and a psychotherapist |
| Q35134582 | Medical choices available for management of menopause |
| Q35299212 | Medical treatment of vertebral osteoporosis |
| Q34655424 | Medroxyprogesterone acetate and dihydrotestosterone induce coronary hyperreactivity in intact male rhesus monkeys |
| Q34550572 | Medroxyprogesterone acetate exacerbates glutamate excitotoxicity |
| Q37241510 | Membrane-initiated actions of estrogen on the endothelium |
| Q40045531 | Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials |
| Q36152764 | Menopausal hormone therapy |
| Q38006917 | Menopausal hormone therapy (MHT): refining our understanding of MHT research, optimally applying results, and considering the future of MHT. |
| Q27022201 | Menopausal hormone therapy and breast cancer mortality: clinical implications |
| Q57288160 | Menopausal hormone therapy and breast cancer: what is the evidence from randomized trials? |
| Q50191723 | Menopausal hormone therapy and gallbladder disease: the Study of Health in Pomerania (SHIP). |
| Q44200265 | Menopausal hormone therapy for cardiovascular protection--unfulfilled expectations |
| Q38626233 | Menopausal hormone therapy for primary prevention: why the USPSTF is wrong |
| Q33644735 | Menopausal hormone therapy: a systematic review of cost-effectiveness evaluations |
| Q38106504 | Menopausal hormone therapy: examining cardiovascular and clinical impacts of treatment. |
| Q36078563 | Menopausal hormone therapy: is there evidence for cardiac protection?. |
| Q37630564 | Menopausal hot flush: is it only a nuisance or also a marker of cardiovascular disease risk? |
| Q37831337 | Menopausal hot flushes and vascular health. |
| Q94324633 | Menopause |
| Q50025650 | Menopause and cardiovascular disease |
| Q39428965 | Menopause and hormone replacement |
| Q33729008 | Menopause and hormone replacement: Part 1. Evaluation and treatment |
| Q82562281 | Menopause hormonal therapy from the urologist's perspective |
| Q37314283 | Menopause, Reproductive Life, Hormone Replacement Therapy, and Bone Phenotype at Age 60-64 Years: A British Birth Cohort |
| Q72989313 | Menopause, oestrogens, SERM's and cardiovascular health in women |
| Q37030684 | Menopause: developing a rational treatment plan |
| Q35561539 | Mental health issues associated with cardiovascular disease in women |
| Q37458317 | Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. |
| Q36570589 | Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women |
| Q36049231 | Metabolic Syndrome versus Framingham Risk Score for Association of Self-Reported Coronary Heart Disease: The 2005 Korean Health and Nutrition Examination Survey |
| Q44567975 | Metabolic syndrome and coronary angiographic disease progression: the Women's Angiographic Vitamin & Estrogen trial |
| Q36062224 | Metabolic syndrome and endothelial dysfunction |
| Q34785799 | Metabolic, endocrine and haemodynamic risk factors in the patient with peripheral arterial disease |
| Q44770881 | Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk? |
| Q43191873 | Methodological considerations of the GRADE method |
| Q34727230 | Methods for evaluating the effects of new hormone replacement therapy compounds on coronary artery disease |
| Q35197492 | MicroRNA-23a participates in estrogen deficiency induced gap junction remodeling of rats by targeting GJA1. |
| Q37608416 | Migraine and cardiocerebrovascular risk in women. |
| Q26853088 | Migraine in women: the role of hormones and their impact on vascular diseases |
| Q33600777 | Migraine, female hormones, and stroke |
| Q34039852 | Migraine, menopause and hormonal replacement therapy |
| Q35538659 | Mining the Complexities of the Estrogen Signaling Pathways for Novel Therapeutics |
| Q34975672 | Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk |
| Q33947465 | Modification of serum lipids and cardiovascular risk by estrogenic active compounds |
| Q36737368 | Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function |
| Q43818871 | Modulation of coronary flow velocity reserve by gender, menstrual cycle and hormone replacement therapy |
| Q48089296 | Modulation of the endocannabinoid system by focal brain ischemia in the rat is involved in neuroprotection afforded by 17beta-estradiol |
| Q34085037 | Molecular mechanisms of estrogen actions on the vasculature |
| Q31122463 | Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board |
| Q34328229 | Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis |
| Q43620328 | Multiple risk factors and population attributable risk for ischemic heart disease mortality in the United States, 1971-1992. |
| Q44445541 | Myocardial infarction during menses: lessons from trials and errors |
| Q58657402 | NM23-H2, an estrogen receptor β-associated protein, shows diminished expression with progression of atherosclerosis |
| Q44111500 | National differences in lipid response to postmenopausal hormone replacement therapy |
| Q45782551 | National estimates and predictors of prescription medication sample use in the United States, 1999–2005 |
| Q37425791 | Natural menopause and risk of stroke in elderly women |
| Q33928985 | Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women |
| Q37349494 | Neither antioxidants nor genistein inhibit the progression of established atherosclerotic lesions in older apoE deficient mice. |
| Q38836985 | New Insight into the Dietary Cause of Atherosclerosis: Implications for Pharmacology |
| Q30396979 | New evidence for cardiac benefit of postmenopausal hormone therapy. |
| Q47647625 | New hope for hormone replacement and the heart? |
| Q44093037 | No antioxidant effect of combined HRT on LDL oxidizability and oxidative stress biomarkers in treated post-menopausal women |
| Q60927238 | Non-ST elevation acute coronary syndrome in women and the elderly: recent updates and stones still left unturned |
| Q92665801 | Non-concealed placebo treatment for menopausal hot flushes: Study protocol of a randomized-controlled trial |
| Q37428590 | Non-genomic regulation of vascular cell function and growth by estrogen. |
| Q73764079 | Non-oral HRT and lipoprotein metabolism. Which progestin-- dydrogesterone or medroxyprogesterone acetate? |
| Q35855139 | Nonestrogen treatment modalities for vasomotor symptoms associated with menopause |
| Q34292071 | Nonhormonal alternatives for the treatment of hot flashes |
| Q34107321 | Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol |
| Q52753334 | Notes on the use of randomised controlled trials to evaluate complex interventions: Community treatment orders as an illustrative case. |
| Q34481800 | Novel agents for managing dyslipidaemia |
| Q36534741 | Novel aspects of endothelium-dependent regulation of vascular tone. |
| Q47571898 | Novel effects of phytoestrogenic soy isoflavones on serum calcium and chloride in premenopausal women: A 2-year double-blind, randomized, placebo-controlled study |
| Q37958061 | Nuclear factor-kappa B inhibitors; a patent review (2006-2010). |
| Q36714151 | Nutrigenetics and nutraceuticals: the next wave riding on personalized medicine |
| Q34238727 | Obesity favors apolipoprotein E- and C-III-containing high density lipoprotein subfractions associated with risk of heart disease |
| Q24558950 | Observational versus experimental studies: what's the evidence for a hierarchy? |
| Q36292523 | Oestrogen and stroke in women: assessment of risk |
| Q32140701 | Oestrogen and the cardiovascular system: the good, the bad and the puzzling. |
| Q43926526 | Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy |
| Q38526762 | Oestrogen replacement in postmenopausal women |
| Q44033173 | Oestrogen supplementation attenuates responses to psychological stress in elderly men rendered hypogonadal after treatment for prostate cancer |
| Q42332484 | Oestrogen, atherosclerosis and cardiovascular disease in women: Epidemiological studies on menopause and hormone replacement therapy |
| Q24648899 | Omega-3 fatty acids for autistic spectrum disorder: a systematic review |
| Q34120300 | On the need to clarify and disseminate contemporary knowledge of hormone therapy initiated near menopause |
| Q73893665 | Opinion survey towards hormone replacement therapy in the prevention of coronary heart disease |
| Q73993528 | Optimal medical management of patients with chronic ischemic heart disease |
| Q44430829 | Oral and transdermal estrogens both lower plasma total homocysteine in male-to-female transsexuals |
| Q44244537 | Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women |
| Q51535496 | Oral contraceptive use and increased plasma concentration of C-reactive protein. |
| Q34039827 | Oral contraceptives, hormone replacement therapy and haemostasis |
| Q42596905 | Oral contraceptives, hormone therapy and cardiovascular risk |
| Q46581962 | Oral estrogen therapy in postmenopausal women is associated with loss of kidney function |
| Q33544590 | Oral micronized progesterone |
| Q43910733 | Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women |
| Q46899634 | Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study |
| Q30491704 | Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data |
| Q34993317 | Osteoporosis in elderly: prevention and treatment |
| Q35692896 | Osteoporosis management in the new millennium. |
| Q33786772 | Osteoporosis: prevention with estrogens in women over 60. |
| Q37864841 | Outcome of lower extremity revascularization for peripheral artery occlusive disease: is there a difference between men and women? |
| Q73852913 | Outcomes improvement following minimally invasive direct coronary artery bypass surgery |
| Q34808085 | Outcomes of lipid-lowering treatment in postmenopausal women |
| Q50449755 | Ovarian Lipid Metabolism Modulates Circulating Lipids in Premenopausal Women. |
| Q35562678 | Ovarian adrenal interactions during the menopausal transition |
| Q42859547 | Ovariectomy does not affect the cardiac sympathovagal balance of female SHR but estradiol does |
| Q51411010 | Ovariectomy enhances SR Ca²⁺ release and increases Ca²⁺ spark amplitudes in isolated ventricular myocytes. |
| Q47278869 | Ovariectomy reinstates the infarct size-limiting effect of postconditioning in female rabbits. |
| Q40725461 | Ovariectomy upregulates expression of estrogen receptors, NOS, and HSPs in porcine platelets |
| Q83314621 | Overview of clinical research design |
| Q37477171 | Overweight and effect of hormone replacement therapy on lipid profiles in postmenopausal women |
| Q34749291 | Parenteral oestrogen in the treatment of prostate cancer: a systematic review |
| Q36147880 | Pathological Importance of the Endothelin-1/ET(B) Receptor System on Vascular Diseases |
| Q35101567 | Pentagastrin-induced release of free fatty acids in healthy volunteers and patients with panic disorder: effect of pretreatment with ethinyl estradiol. |
| Q44369967 | Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri and postmenopausal women |
| Q44434592 | Perinatal exposure to diethylstilbestrol improves olfactory discrimination learning in male and female Swiss-Webster mice |
| Q38917824 | Periodontal disease and women's health |
| Q30982133 | Periodontal disease-associated micro-organisms in peri-menopausal and post-menopausal women using or not using hormone replacement therapy. A two-year follow-up study |
| Q34714712 | Peripheral arterial disease: medical care and prevention of complications |
| Q35934073 | Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations |
| Q77377835 | Persistence with estrogen therapy in a postmenopausal Medicaid population |
| Q40496235 | Personal use of HRT by postmenopausal women doctors and doctors' wives in the north of Italy. |
| Q34272198 | Perspectives in hormone replacement therapy |
| Q36920505 | Perspectives on hormone replacement therapy: the Women's Health Initiative and new observational studies sampling the overall population |
| Q38674511 | Pharmaceutically treated anxiety but not depression prior to cancer diagnosis predicts the onset of cardiovascular disease among breast cancer survivors |
| Q30841046 | Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: a review of the data and identification of knowledge gaps |
| Q33918549 | Pharmacodynamics of oestrogens and progestogens |
| Q36635499 | Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven? |
| Q36352761 | Pharmacogenetics of multigenic disease: heart disease as an example |
| Q38696985 | Pharmacogenomics to Revive Drug Development in Cardiovascular Disease |
| Q43899368 | Pharmacologic preconditioning of estrogen by activation of the myocardial adenosine triphosphate-sensitive potassium channel in patients undergoing coronary angioplasty |
| Q35976827 | Pharmacologic treatment of type 2 diabetic dyslipidemia |
| Q34515458 | Pharmacological approaches to preserving and restoring coronary endothelial function |
| Q73289396 | Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist? |
| Q46706675 | Pharmacological investigations of the unique herbal formula Menoprogen in rats: estrogenic activity and mechanism |
| Q33795849 | Pharmacological management of osteoporosis in postmenopausal women: a comparative review |
| Q28268346 | Pharmacology of estrogens and progestogens: influence of different routes of administration |
| Q34181898 | Pharmacotherapy following myocardial infarction--a review of current treatment practices |
| Q35194552 | Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety |
| Q45008361 | Physical activity and cardiovascular risk factors at menopause: the Nord-Trøndelag health study |
| Q34799103 | Physical activity, hormone replacement therapy, and the presence of coronary calcium in midlife women |
| Q44478596 | Physiological testosterone replacement and arterial endothelial function in men. |
| Q37138656 | Phyto-oestrogens and bone health |
| Q54233108 | Phytoestrogens Activate the Estrogen Receptor in HepG2 Cells. |
| Q33916551 | Phytoestrogens and cardiovascular health. |
| Q24243494 | Phytoestrogens for vasomotor menopausal symptoms |
| Q34380530 | Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective |
| Q35074555 | Phytoestrogens: endocrine disrupters or replacement for hormone replacement therapy? |
| Q36739255 | Pitfalls of the WHIs: Women's Health Initiative |
| Q36176376 | Placebo adherence and mortality in the Heart and Estrogen/Progestin Replacement Study |
| Q26852547 | Placebo controlled trials in neuromyelitis optica are needed and ethical |
| Q40565085 | Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy. |
| Q29615729 | Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study |
| Q33282914 | Platelet adhesion onto immobilized fibrinogen under arterial and venous in-vitro flow conditions does not significantly differ between men and women |
| Q37658732 | Platelet hyperfunction as risk factor for chronic and acute coronary events |
| Q34767292 | Platelet reactivity and genetics down on the pharm. |
| Q34319478 | Pleiotropic effects of statins and their clinical significance |
| Q33926055 | Polymorphisms in the platelet-specific collagen receptor GP6 are associated with risk of nonfatal myocardial infarction in Caucasians. |
| Q73795280 | Population-based study of age at menopause and ultrasound assessed carotid atherosclerosis: The Tromsø Study |
| Q33653551 | Position of the American Dietetic Association and Dietitians of Canada: women's health and nutrition |
| Q35576667 | Positive association of the hepatic lipase gene polymorphism c.514C > T with estrogen replacement therapy response |
| Q44009191 | Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate |
| Q44563404 | Positive impact of hormone replacement therapy on the fibrinolytic system: a long-term randomized controlled study in healthy postmenopausal women |
| Q36945220 | Post menopausal hormones and measures of subclinical atherosclerosis: the multi-ethnic study of atherosclerosis |
| Q35678406 | Post-genomic update on a classical candidate gene for coronary artery disease: ESR1 |
| Q34039846 | Post-menopausal hormone replacement therapy and stroke risk |
| Q40139564 | Post-menopausal hormone therapy and cardiovascular events: a new paradigm based on pharmacogenetics? |
| Q38013806 | Post-myocardial infarction hormone therapy revisited |
| Q34037822 | Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy |
| Q34746437 | Postmenopausal estrogen therapy and depressive symptoms in older women |
| Q37314727 | Postmenopausal hormonal therapy: Current status |
| Q51554179 | Postmenopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension. |
| Q34774237 | Postmenopausal hormone replacement therapy and atherosclerosis. |
| Q34482151 | Postmenopausal hormone replacement therapy as antiatherosclerotic therapy |
| Q33902248 | Postmenopausal hormone replacement therapy for chronic disease prevention: results from the Women's Health Initiative trial |
| Q37644027 | Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease. Recommendation statement from the Canadian Task Force on Preventive Health Care |
| Q44369938 | Postmenopausal hormone replacement therapy in the light of the women's health initiative trial |
| Q34771470 | Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model |
| Q33683302 | Postmenopausal hormone replacement, risk estimators for coronary artery disease and cardiovascular protection |
| Q37234323 | Postmenopausal hormone therapy and cardiovascular disease in perspective |
| Q36645889 | Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women |
| Q38165230 | Postmenopausal hormone therapy and coronary heart disease in early postmenopausal women. |
| Q74106681 | Postmenopausal hormone therapy and coronary heart disease: clinical implications of recent randomized trial results |
| Q34727190 | Postmenopausal hormone therapy and the risk of cardiovascular disease: the epidemiologic evidence |
| Q47842567 | Postmenopausal hormone therapy in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil): who still uses it? |
| Q33757741 | Postmenopausal hormone therapy, SERMs, and coronary heart disease in women |
| Q35692889 | Postmenopausal hormone therapy: a concise guide to therapeutic uses, formulations, risks, and alternatives |
| Q30451123 | Postmenopausal hormone therapy: an Endocrine Society scientific statement. |
| Q35732023 | Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life |
| Q35948687 | Postmenopausal hormone therapy: lessons from observational and randomized studies |
| Q38082563 | Postmenopausal hormone therapy: risks and benefits |
| Q53350994 | Postmenopausal hormone therapy: the pros and cons. |
| Q28221869 | Postmenopausal hormones and coronary artery disease: potential benefits and risks |
| Q74194728 | Postmenopausal hormones and heart disease |
| Q33917334 | Postmenopausal hypertension |
| Q34044762 | Postmenopausal osteoporosis. Strategies for preventing bone loss, avoiding fracture |
| Q73343201 | Postmenopause hormone treatment in women with NIDDM or impaired glucose tolerance: the MEDIA randomized clinical trial |
| Q35071491 | Potential age-dependent effects of estrogen on neural injury |
| Q46664316 | Potential health benefits of continuous LNG-IUS combined with parenteral ERT for seamless menopausal transition and beyond--a commentary based on clinical experience |
| Q30327667 | Practical guidelines for multiplicity adjustment in clinical trials. |
| Q33668351 | Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden |
| Q34735835 | Prediction of random effects in linear and generalized linear models under model misspecification |
| Q34601259 | Predictive probability of success and the assessment of futility in large outcomes trials |
| Q38134402 | Predictors of cardiovascular risk in women |
| Q36986108 | Predisposing factors related to shunt-dependent chronic hydrocephalus after aneurysmal subarachnoid hemorrhage |
| Q45739775 | Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus G |
| Q34688088 | Premature ovarian failure (POF): discordance between somatic and reproductive aging |
| Q33278956 | Premature ovarian failure: a review |
| Q33681494 | Prescribing postmenopausal hormone therapy to women in their 50s in the post-Women's Health Initiative era. |
| Q34724157 | Prescriptions for chronic high-dose cyclooxygenase-2 inhibitors are often inappropriate and potentially dangerous |
| Q64131447 | Prevalence of and factors associated with hormone replacement therapy counseling: results from the 1994 National Health Interview Survey |
| Q37499363 | Preventing and Experiencing Ischemic Heart Disease as a Woman: State of the Science: A Scientific Statement From the American Heart Association |
| Q34087262 | Preventing fractures in postmenopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents |
| Q35722908 | Preventing type II diabetes mellitus |
| Q34003407 | Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment |
| Q38095646 | Prevention and treatment of cardiovascular disease in women: the obstetric-gynecologist's point of view. |
| Q77896123 | Prevention and treatment of osteoporosis in the elderly |
| Q34140721 | Prevention and treatment of venous thromboembolism during HRT: current perspectives |
| Q43360167 | Prevention in the year 2002: some news, some issues |
| Q35201099 | Prevention of bone resorption by intake of phytoestrogens in postmenopausal women: a meta-analysis |
| Q34993307 | Prevention of cardiovascular diseases. Coronary artery disease, congestive heart failure, and stroke |
| Q36295235 | Prevention of cardiovascular events in elderly people |
| Q33986362 | Prevention of coronary artery disease |
| Q42920313 | Prevention of coronary artery disease in men: Male hormone, female hormone, or both? |
| Q37362761 | Prevention of coronary heart disease in women |
| Q33859347 | Prevention of coronary heart disease. Part I. Primary prevention |
| Q33857984 | Prevention of coronary heart disease. Part II. Secondary prevention, detection of subclinical disease, and emerging risk factors |
| Q34655430 | Prevention of coronary hyperreactivity in preatherogenic menopausal rhesus monkeys by transdermal progesterone |
| Q78801080 | Preventive care for the menopausal woman |
| Q38500893 | Primary and secondary prevention of ischemic heart disease in women |
| Q84230884 | Primary biliary cirrhosis |
| Q37968650 | Primary prevention of cardiovascular disease with HRT. |
| Q38399459 | Primary prevention of cardiovascular disease with hormone replacement therapy |
| Q33731870 | Primary prevention of coronary heart disease in postmenopausal women |
| Q34993299 | Primary prevention of disease of old age. |
| Q34140730 | Primary prevention of heart disease in women |
| Q22306369 | Primary prevention of ischemic stroke |
| Q45236376 | Principles of drug literature evaluation for observational study designs |
| Q55260964 | Prioritising Risk Factors for Type 2 Diabetes: Causal Inference through Genetic Approaches. |
| Q44343973 | Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment |
| Q38103064 | Progesterone and cerebral ischaemia: the relevance of ageing |
| Q37295760 | Progesterone enhances vascular endothelial cell migration via activation of focal adhesion kinase. |
| Q44750448 | Progesterone for hot flush and night sweat treatment--effectiveness for severe vasomotor symptoms and lack of withdrawal rebound |
| Q42510143 | Progesterone regulation of vascular thromboxane A(2) receptors in rhesus monkeys |
| Q37499223 | Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women |
| Q46039879 | Progestin may modify the effect of low-dose hormone therapy on mammographic breast density. |
| Q33694958 | Progestins in the menopause |
| Q44793608 | Progestins initiate adverse events of menopausal estrogen therapy |
| Q36109111 | Progestogen safety and tolerance in hormonal replacement therapy |
| Q45173121 | Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy. |
| Q37453973 | Progress in osteoporosis and fracture prevention: focus on postmenopausal women |
| Q46775102 | Progressive diastolic dysfunction in the female mRen(2). Lewis rat: influence of salt and ovarian hormones |
| Q91603392 | Prophylactic salpingo-oophorectomy & surgical menopause for inherited risks of cancer: the need to identify biomarkers to assess the theoretical risk of premature coronary artery disease |
| Q35089986 | Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/-progestogen) treatments. |
| Q35181725 | Pros and cons of thrombophilia testing: pros. |
| Q37727226 | Proton pump inhibitors and clopidogrel: is it a significant drug interaction? |
| Q35185845 | Psychosocial factors and public health: a suitable case for treatment? |
| Q33843668 | Putting prevention into daily practice |
| Q79299403 | Putting prevention into daily practice |
| Q41702210 | Quality measurement issues in heart disease in women |
| Q34498749 | Quality of life and hormones after sex reassignment surgery. |
| Q36320729 | Quantitative proteomic analysis reveals novel mitochondrial targets of estrogen deficiency in the aged female rat heart |
| Q36957797 | Race and Sex Differences in the Incidence and Prognostic Significance of Silent Myocardial Infarction in the Atherosclerosis Risk in Communities (ARIC) Study. |
| Q34623933 | Race, ethnicity, and geography: disparities in heart disease in women of color. |
| Q34843083 | Racial and ethnic disparities in coronary heart disease in women: prevention, treatment, and needed interventions |
| Q44018603 | Raloxifene and cardiovascular disease |
| Q43515049 | Raloxifene and estrogen reduces progression of advanced atherosclerosis--a study in ovariectomized, cholesterol-fed rabbits |
| Q43846868 | Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression |
| Q38825454 | Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women |
| Q51814993 | Raloxifene prevents endothelial dysfunction in aging ovariectomized female rats. |
| Q51456939 | Raloxifene reduces blood pressure in hypertensive animals after ovarian hormone deprivation. |
| Q45267520 | Raloxifene relaxes rat intrarenal arteries by inhibiting Ca2+ influx. |
| Q33703846 | Raloxifene, a new selective estrogen receptor modulator |
| Q44489365 | Raloxifene, conjugated oestrogen and endothelial function in postmenopausal women |
| Q30838964 | Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women |
| Q34030136 | Raloxifene: a review of its use in postmenopausal osteoporosis |
| Q44791857 | Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers |
| Q36993488 | Rapid actions of androgens |
| Q31079547 | Rapid changes in cardiac myofilament function following the acute activation of estrogen receptor-alpha |
| Q33968176 | Rapid progress for non-nuclear estrogen receptor signaling |
| Q34964032 | Rapid vascular cell responses to estrogen and membrane receptors |
| Q36163230 | Rapid, estrogen receptor-mediated signaling: why is the endothelium so special? |
| Q40081930 | Rational combination therapy in refractory migraine |
| Q42618508 | Rationale, design and methods of the CASHMERE study. |
| Q36494078 | Re-adopting classical nuclear receptors by cholesterol metabolites |
| Q79302366 | Reality of menopausal hormone replacement therapy by French gynaecologists: OCEANIDES, a transversal and longitudinal national epidemiology study |
| Q34149951 | Reasonable osteoporosis prevention: hormone replacement therapy, SERM, or bisphosphonate? |
| Q81428041 | Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial |
| Q21195226 | Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype |
| Q33693138 | Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women: 1988 to 2004. |
| Q35178631 | Recent concerns surrounding HRT. |
| Q36946779 | Recent epidemiological evidence relevant to the clinical management of the menopause |
| Q33475114 | Recent trends in breast cancer incidence in US white women by county-level urban/rural and poverty status |
| Q33828714 | Recommendations for estrogen and progestin replacement in the climacteric and postmenopause. European Progestin Club |
| Q36428565 | Recommendations for raloxifene use in daily clinical practice in the Swiss setting |
| Q35896656 | Recommendations for the diagnosis and management of osteoporosis: a local perspective. |
| Q37853272 | Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women: proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. |
| Q50457468 | Red clover isoflavones enriched with formononetin lower serum LDL cholesterol-a randomized, double-blind, placebo-controlled study. |
| Q34228809 | Reducing cardiovascular risk in diabetes. Which factors to modify first? |
| Q34645011 | Reducing global risk for cardiovascular disease: using lifestyle changes and pharmacotherapy |
| Q28361065 | Reduction of oxidative stress and AT1 receptor expression by the selective oestrogen receptor modulator idoxifene |
| Q24799163 | Reduction of post injury neointima formation due to 17beta-estradiol and phytoestrogen treatment is not influenced by the pure synthetic estrogen receptor antagonist ICI 182,780 in vitro |
| Q53634487 | Regulation of Glucose Handling by the Skeleton: Insights From Mouse and Human Studies. |
| Q44881999 | Regulatory molecules for coronary expressions of VEGF and its angiogenic receptor KDR in hypoestrogenic middle-aged female rats |
| Q34739277 | Relation between hormone replacement therapy and ischaemic heart disease in women: prospective observational study |
| Q37571516 | Relationship between Serum Levels of Metalloproteinase-8 and Tissue Inhibitor of Metalloproteinases-1 and Exercise Test Results in Postmenopausal Women. |
| Q33895146 | Relationship between benign prostatic hyperplasia and history of coronary artery disease in elderly men. |
| Q33557595 | Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study |
| Q43602393 | Relationship between the angiotensin-converting enzyme genotype and the forearm vasodilator response to estrogen replacement therapy in postmenopausal women |
| Q47844292 | Relationship of peripheral arterial compliance and standard cardiovascular risk factors |
| Q36352735 | Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapy |
| Q36835818 | Relaxin as a natural agent for vascular health |
| Q34198010 | Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies |
| Q51819816 | Renal function predicts cardiovascular outcomes in southern Italian postmenopausal women. |
| Q43723152 | Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease |
| Q51533934 | Reporting on post-menopausal hormone therapy: an analysis of gynaecologists' web pages. |
| Q41112065 | Reproductive endocrinology: Don't be so quick to stop hormone-replacement therapy |
| Q33786777 | Reproductive history and cardiovascular disease risk in postmenopausal women: a review of the literature |
| Q34919996 | Reproductive hormones and cardiovascular disease mechanism of action and clinical implications |
| Q34043346 | Research into Specific Modulators of Vascular Sex Hormone Receptors in the Management of Postmenopausal Cardiovascular Disease |
| Q44198871 | Research needs for environmental health risk assessment |
| Q43911044 | Resistive index of renal artery and blood pressure in postmenopausal women. |
| Q35233116 | Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients. |
| Q44547302 | Response to sex hormones differs in atherosclerosis-susceptible and -resistant mice. |
| Q27006022 | Results of observational studies: analysis of findings from the Nurses' Health Study |
| Q34742537 | Review of evidence and explanations for suboptimal screening and treatment of dyslipidemia in women. A conceptual model. |
| Q34211142 | Revisiting estrogen: efficacy and safety for postmenopausal bone health |
| Q28344803 | Rheumatology: 15. Osteoporosis |
| Q33786268 | Risk assessment of the menopausal patient |
| Q36540458 | Risk factor and prediction modeling for sudden cardiac death in women with coronary artery disease |
| Q33720834 | Risk factors for age-related maculopathy |
| Q34562508 | Risk factors for breast cancer |
| Q35771145 | Risk factors for cardiovascular disease and hormone therapy in women |
| Q44652580 | Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study |
| Q73236487 | Risk factors for venous thromboembolism |
| Q46916582 | Risk of cardiovascular disease in relation to the use of combined postmenopausal hormone therapy: detection bias and resolution of discrepant findings in two Women's Health Initiative studies |
| Q43244412 | Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations |
| Q36536307 | Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients |
| Q34039811 | Risks and benefits of hormone replacement therapy |
| Q34899934 | Risks and benefits of hormone replacement therapy: the evidence speaks |
| Q36069532 | Risks and benefits of menopausal hormone therapy in postmenopausal Chinese women |
| Q47311531 | Role of Estrogens in the Regulation of Liver Lipid Metabolism |
| Q50989642 | Role of GPER in estrogen-dependent nitric oxide formation and vasodilation. |
| Q42372893 | Role of Sex Hormones in the Control of Vegetative and Metabolic Functions of Middle-Aged Women |
| Q35212546 | Role of endothelial dysfunction in insulin resistance |
| Q27026798 | Role of estrogen in diastolic dysfunction |
| Q46727875 | Role of inflammatory cytokines in the effect of estradiol on atheroma. |
| Q35590308 | Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women |
| Q35757584 | Role of the nonhuman primate for research related to women's health |
| Q36978158 | Rosuvastatin in elderly patients |
| Q77491728 | ST-Segment Elevation Myocardial Infarction |
| Q82669932 | STROBE and STREGA: instruments for improving transparency and quality of reporting scientific results |
| Q38700757 | Safety and benefit considerations for menopausal hormone therapy |
| Q46966056 | Safety and efficacy of hormonal therapy in menopausal kidney-allograft recipients. |
| Q35618441 | Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring and management. |
| Q35911827 | Safety of a new oral contraceptive containing drospirenone |
| Q45017084 | Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study |
| Q33726316 | Schisandrae Fructus Reduces Symptoms of 4-Vinylcyclohexene Diepoxide-Induced Ovarian Failure in Mice. |
| Q33786237 | Screening for cardiovascular disease. Concepts, conflicts, and consensus |
| Q35861443 | Screening, supplements and the use of hormonal replacement therapy in postmenopausal women in a family medicine department prior to the publication of the Woman's Health Initiative report. |
| Q84850268 | Secondary prevention of ischaemic cardiac events |
| Q93501271 | Secondary prevention of ischaemic cardiac events |
| Q43771449 | Selected contribution: estrogen receptor-alpha gene transfer inhibits proliferation and NF-kappaB activation in VSM cells from female rats |
| Q34326845 | Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer |
| Q74743735 | Selective estrogen receptor modulators |
| Q34399549 | Selective estrogen receptor modulators and coronary heart disease |
| Q36799439 | Selective estrogen receptor modulators and risk for coronary heart disease. |
| Q85176448 | Selective estrogen receptor modulators promising for cardiac syndrome X |
| Q33841014 | Selective estrogen receptor modulators--a new age of estrogens in cardiovascular disease? |
| Q33649621 | Selective estrogen receptor modulators: a look ahead |
| Q73765058 | Self-rated health, life satisfaction and personal characteristics of post-menopausal women under estrogen replacement therapy |
| Q34414882 | Self-reported changes in providers' hormone therapy prescribing and counseling practices after the Women's Health Initiative |
| Q73281489 | Sequentially combined hormone replacement therapy reduces impedance to flow within the uterine and central retinal arteries in healthy postmenopausal women |
| Q37255465 | Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction |
| Q44571336 | Serum lipids and apolipoproteins in Greek postmenopausal women: association with estrogen, estrogen-progestin, tibolone and raloxifene therapy |
| Q39171887 | Sex Hormones and Sex Chromosomes Cause Sex Differences in the Development of Cardiovascular Diseases |
| Q46745482 | Sex and ethnic/racial-specific risk factors for gallbladder disease |
| Q38751037 | Sex differences in cardiovascular ageing |
| Q30234726 | Sex differences in cardiovascular disease - Impact on care and outcomes |
| Q33699212 | Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010 |
| Q37597000 | Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults |
| Q35509492 | Sex differences in inflammation during atherosclerosis |
| Q88954382 | Sex differences in lipid and lipoprotein metabolism |
| Q26801284 | Sex differences in predictors of ischemic stroke: current perspectives |
| Q82035418 | Sex differences in stroke |
| Q37149840 | Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes |
| Q34077852 | Sex differences in the risk of stroke and HbA(1c) among diabetic patients |
| Q73989803 | Sex differences in uric acid and risk factors for coronary artery disease |
| Q36867315 | Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease |
| Q37651567 | Sex hormone therapy and progression of cardiovascular disease in menopausal women |
| Q36854152 | Sex hormones and the cardiovascular system: effects on arterial function in women. |
| Q60530603 | Sex hormones and venous thromboembolism – from contraception to hormone replacement therapy |
| Q40218728 | Sex hormones, vascular function and the outcome of hormone replacement therapy in cardiovascular disease |
| Q51746252 | Sex influences the susceptibility to reperfusion-induced sustained ventricular tachycardia and beta-adrenergic receptor blockade in conscious rats. |
| Q24652102 | Sex, sex steroids, and brain injury |
| Q36185871 | Sex, stroke, and inflammation: the potential for estrogen-mediated immunoprotection in stroke |
| Q96955188 | Sex-Specific Effects of the Nlrp3 Inflammasome on Atherogenesis in LDL Receptor-Deficient Mice |
| Q26996309 | Sex-based differences in cardiac ischaemic injury and protection: therapeutic implications |
| Q96024722 | Sex-opposed inflammatory effects of 27-hydroxycholesterol are mediated via differences in estrogen signaling |
| Q33685081 | Sex-specific responses to stroke |
| Q35993886 | Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes |
| Q91753021 | Sexual Activity in Patients with Cardiac Diseases |
| Q37504674 | Sexual dimorphism in the aging kidney: differences in the nitric oxide system |
| Q89054799 | Sexual dimorphism of cardiometabolic dysfunction: Gut microbiome in the play? |
| Q37192036 | Sexual dimorphism of the aging kidney: role of nitric oxide deficiency |
| Q37484915 | Sexual dimorphism, the aging kidney, and involvement of nitric oxide deficiency |
| Q37003151 | Sexual dimorphism: the aging kidney, involvement of nitric oxide deficiency, and angiotensin II overactivity |
| Q35563180 | Sexual function and the older woman |
| Q33783545 | Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. |
| Q39337263 | Should symptomatic menopausal women be offered hormone therapy? |
| Q35117184 | Should this study change my practice? |
| Q43744365 | Should we treat the andropause? |
| Q34041102 | Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials |
| Q44242897 | Significant predictors of poor prognosis in women aged |
| Q24289462 | Six persistent research misconceptions |
| Q37799910 | Social conditions as fundamental causes of health inequalities: theory, evidence, and policy implications |
| Q57127662 | Socioeconomic Position and Hormone Replacement Therapy Use: Explaining the Discrepancy in Evidence From Observational and Randomized Controlled Trials |
| Q50542589 | Socioeconomic status and use of postmenopausal hormone replacement therapy among Danish women. |
| Q35056537 | Soy foods and soybean isoflavones and menopausal health |
| Q89733605 | State of the Science in Women's Cardiovascular Disease: A Canadian Perspective on the Influence of Sex and Gender |
| Q31729029 | Statin trials in progress: unanswered questions |
| Q34991463 | Statins and menopause |
| Q36070930 | Statins and osteoporosis: a clinical review |
| Q43861569 | Statins as novel therapies for osteoporosis? |
| Q31729174 | Statins, hormones, and women: benefits and drawbacks for atherosclerosis and osteoporosis |
| Q37132137 | Stem cells for cardiovascular repair - the challenges of the aging heart |
| Q73544342 | Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques |
| Q24198081 | Steroid sex hormones for lower limb atherosclerosis |
| Q33908587 | Steroid sex hormones for lower limb atherosclerosis. |
| Q45127615 | Stroke Hormones and Outcomes in Women (SHOW) study: is the 'healthy-user effect' valid for women after stroke? |
| Q37058753 | Stroke and the female brain |
| Q35757557 | Stroke in the female: role of biological sex and estrogen |
| Q37080269 | Stroke in women: risk and prevention throughout the lifespan |
| Q37868357 | Stroke in young women. |
| Q33590651 | Submaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin |
| Q36234919 | Sugar, sex, and TGF-β in diabetic nephropathy |
| Q33553921 | Survival advantage in Medicare patients receiving drug-eluting stents compared with bare metal stents: real or artefactual? |
| Q39574240 | Synthesis and investigations on the oxidative degradation of C3/C5-alkyl-1,2,4-triarylpyrroles as ligands for the estrogen receptor |
| Q35162636 | Systemic effects of vaginally administered estrogen therapy: a review |
| Q41856851 | Tailoring cardiovascular risk assessment and prevention for women: One size does not fit all. |
| Q51767582 | Tamoxifen treatment of myocardial infarcted female rats exacerbates scar formation. |
| Q36695459 | Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids |
| Q42578843 | Tapering versus cold turkey: symptoms versus successful discontinuation of menopausal hormone therapy |
| Q38367355 | Targeting lipoprotein (a): an evolving therapeutic landscape |
| Q73835753 | Targeting of hormone replacement therapy immediately after menopause |
| Q37008834 | Targets for regulating angiogenesis in the ageing endothelium |
| Q35417608 | Terms in reproductive and perinatal epidemiology: I. Reproductive terms |
| Q35197858 | Testosterone and atherosclerosis |
| Q37037827 | Testosterone and cardiovascular disease in men. |
| Q35582685 | Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life |
| Q37376153 | Testosterone replacement therapy in the climacteric: benefits beyond sexuality. |
| Q33167115 | Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review |
| Q34113414 | That was the year that was: an evidence-based clinical geriatrics update 1998-1999. |
| Q36394541 | The "Mevalonate hypothesis": a cholesterol-independent alternative for the etiology of atherosclerosis |
| Q34161400 | The 2012 hormone therapy position statement of: The North American Menopause Society |
| Q77087785 | The AHA guidelines on hormone replacement therapy and cardiovascular disease. American Heart Association |
| Q33392407 | The Asp298 allele of endothelial nitric oxide synthase is a risk factor for myocardial infarction among patients with type 2 diabetes mellitus |
| Q36989827 | The Association between Symptoms of Dry Eye Syndrome and Metabolic Outcome in a General Population in Korea |
| Q33917513 | The Challenges of Prevention, Diagnosis and Treatment of Ischemic Heart Disease in Women |
| Q48378027 | The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers |
| Q90194537 | The Controversial History of Hormone Replacement Therapy |
| Q56888461 | The Economics and Management of Osteoporosis in Postmenopausal Women |
| Q26821782 | The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk |
| Q30234123 | The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis |
| Q39348201 | The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy |
| Q35551803 | The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function |
| Q21563448 | The Haunting of Medical Journals: How Ghostwriting Sold “HRT” |
| Q35179555 | The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention |
| Q33821249 | The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain? |
| Q36807388 | The Importance of Biological Sex and Estrogen in Rodent Models of Cardiovascular Health and Disease |
| Q42085888 | The Importance of Considering Sex Differences in Translational Stroke Research |
| Q35349263 | The Lifestyle Interventions and Independence for Elders Study: design and methods |
| Q73893655 | The Nurses' Health Study: unresolved issues after 20-years follow-up |
| Q44684635 | The Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study: design and baseline characteristics |
| Q56888467 | The Pharmacoeconomics of Hormone Replacement Therapy |
| Q38927944 | The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia. |
| Q41689704 | The Potential of SERMs for Reducing the Risk of Coronary Heart Disease |
| Q73893657 | The Queen... is naked! |
| Q47154432 | The Rise and Fall of Estrogen Therapy: Is Testosterone for "Manopause" Next? |
| Q60923922 | The Role of Menopausal Hormone Therapy in Reducing All-cause Mortality in Postmenopausal Women Younger than 60 Years: An Adaptive Meta-analysis |
| Q33275630 | The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial |
| Q43408070 | The absolute risk of recurrent myocardial infarction is similar amongst both sexes: MONICA Iceland Study 1981-1999. |
| Q33688763 | The adverse effects of hormone replacement therapy |
| Q53372472 | The aging woman: the role of medical therapy |
| Q33809318 | The agonising negative trend in monitoring of clinical trials |
| Q48347945 | The assessment of efficacy of Diascorea alata for menopausal symptom treatment in Taiwanese women |
| Q53644185 | The association between hormonal and reproductive factors and hand osteoarthritis. |
| Q77220380 | The association between low bone mass at the menopause and cardiovascular mortality |
| Q35590304 | The association between soy nut consumption and decreased menopausal symptoms |
| Q37126271 | The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program |
| Q57109352 | The association of oestrogen receptor α-haplotypes with cardiovascular risk factors in the British Women's Heart and Health Study |
| Q81418099 | The associations of hormone replacement therapy and preventive practices in minority women |
| Q44249441 | The atheroprotective effect of 17 beta-estradiol is not altered in P-selectin- or ICAM-1-deficient hypercholesterolemic mice. |
| Q30478113 | The atheroprotective effect of 17beta-estradiol depends on complex interactions in adaptive immunity |
| Q35907159 | The beneficial effects of massage therapy for insomnia in postmenopausal women |
| Q51494719 | The benefits of oestrogens on postprandial lipid metabolism are lost in post-menopausal women with Type 2 diabetes. |
| Q22299214 | The breast cancer epidemic: 10 facts |
| Q36739272 | The cardiovascular effects of selective estrogen receptor modulators. |
| Q48583587 | The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. |
| Q90153199 | The clinical impact of estrogen loss on cardiovascular disease in menopausal females |
| Q35548796 | The clinical implications of endothelial dysfunction |
| Q73303494 | The clinical management guidelines of the Sociedad Española de Cardiología in acute myocardial infarct |
| Q37098181 | The decline effect in cardiovascular medicine: is the effect of cardiovascular medicine and stent on cardiovascular events decline over the years? |
| Q39347912 | The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women. |
| Q47429072 | The drug industry and medical practice--the case of menopausal hormone therapy in Estonia |
| Q33653638 | The effect of 17 beta-estradiol on intracellular calcium homeostasis in human endothelial cells |
| Q44205516 | The effect of 17beta-estradiol on endothelial and inflammatory markers in postmenopausal women: a randomized, controlled trial |
| Q35200903 | The effect of 17β-estradiol on cholesterol content in human macrophages is influenced by the lipoprotein milieu |
| Q43813852 | The effect of continuous combined hormone replacement therapy on arterial reactivity in postmenopausal women with established angina pectoris |
| Q46797831 | The effect of different preparations of hormone therapy on tumor necrosis factor-alpha levels in women with surgical menopause. |
| Q44699035 | The effect of flax seed cultivars with differing content of alpha-linolenic acid and lignans on responses to mental stress |
| Q81640805 | The effect of hormone replacement therapy cessation on heart rate variability in postmenopausal women |
| Q44303479 | The effect of hormone replacement therapy on atherosclerotic severity in relation to ESR1 genotype in postmenopausal women |
| Q79754070 | The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results |
| Q46169610 | The effect of oral evening primrose oil on menopausal hot flashes: a randomized clinical trial. |
| Q43612139 | The effect of oral hormone replacement therapy on lipoprotein profile, resistance of LDL to oxidation and LDL particle size. |
| Q44166331 | The effect of oxidative stress on ERalpha and ERbeta expression |
| Q39129668 | The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights. |
| Q46526827 | The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer |
| Q44019594 | The effect of the phytoestrogen genistein on plasma nitric oxide concentrations, endothelin-1 levels and endothelium dependent vasodilation in postmenopausal women |
| Q35602242 | The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial |
| Q82213153 | The effects of 20-hydroxyecdysone and 17β-estradiol on the skin of ovariectomized rats |
| Q42165321 | The effects of a soy rich diet on serum lipids: the Menfis randomized trial. |
| Q36229442 | The effects of aromatase inhibitors on lipids and thrombosis |
| Q46061292 | The effects of continuous combined oral estradiol and norethisterone on pulsatility index in internal carotid and uterine arteries in early postmenopausal Taiwanese women---a preliminary study |
| Q45147410 | The effects of different hormone treatment on endothelial function in healthy postmenopausal women |
| Q34951934 | The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review |
| Q42620817 | The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study |
| Q43293543 | The effects of hormone replacement therapy on myocardial performance in early postmenopausal women |
| Q51557692 | The effects of hormone replacement therapy on plasma lipids in type II diabetes. |
| Q34049729 | The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of literature |
| Q34978893 | The effects of postmenopausal hormone replacement therapy on hemostatic variables: a meta-analysis of 46 studies |
| Q51559402 | The effects of six months of treatment with a low-dose of conjugated oestrogens in menopausal women. |
| Q38482584 | The effects of transdermal estradiol alone or with cyclical dydrogesterone on markers of cardiovascular disease risk in postmenopausal women with type 2 diabetes: a pilot study |
| Q51972859 | The effects of transdermal estradiol on the response to mental stress in postmenopausal women: a randomized trial. |
| Q34134001 | The endothelium: a gynecological and obstetric point of view. |
| Q53521312 | The estrogen replacement and atherosclerosis (ERA) study: study design and baseline characteristics of the cohort. |
| Q53473765 | The ethics of aggregation and hormone replacement therapy. |
| Q33873102 | The evolving role of specific estrogen receptor modulators (SERMs) |
| Q33786786 | The first clinical synthesis conference on hormone replacement therapy: new perspectives for HRT? |
| Q33544850 | The heart and estrogen/progestin replacement study (HERS). |
| Q35839377 | The heart of the matter of opinion and evidence: the value of evidence-based medicine |
| Q45557445 | The history of hormone therapy use and recent controversy related to heart disease and breast cancer arising from prevention trial outcomes |
| Q39652573 | The impact and management of symptoms experienced at midlife: a community-based study of women in northeast Scotland |
| Q34724578 | The impact of clinical trials on the use of hormone replacement therapy. A population-based study |
| Q34722892 | The impact of comorbidities on hormone use. After the 2000 release of the Women's Health Initiative |
| Q33814554 | The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers |
| Q52666783 | The impact of menopausal hormone therapy (MHT) on cardiac structure and function: Insights from the UK Biobank imaging enhancement study. |
| Q42513272 | The impact of ovariectomy on cardiac excitation-contraction coupling is mediated through cAMP/PKA-dependent mechanisms |
| Q37585161 | The impact of sex hormone changes on bone mineral deficit in chronic renal failure |
| Q34602890 | The impact of testosterone imbalance on depression and women's health |
| Q46244173 | The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women |
| Q26795584 | The influence of endogenous and exogenous sex hormones on systemic lupus erythematosus in pre- and postmenopausal women |
| Q73033327 | The influence of gender on the outcome of coronary artery bypass surgery |
| Q35012529 | The interaction between metabolism, cancer and cardiovascular disease, connected by 27-hydroxycholesterol |
| Q34014713 | The iron hypothesis:does iron play a role in atherosclerosis? |
| Q37298238 | The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability. |
| Q44593167 | The lipid and clinical effects of sequential transdermal estradiol and estradiol/norethisterone acetate in 674 women |
| Q43975427 | The long-term effect of estriol on endothelial function and bone mineral density in octogenarian women |
| Q46877640 | The long-term effects of tibolone on aortic stiffness and endothelial function |
| Q34421664 | The mechanisms of thrombotic risk induced by hormone replacement therapy |
| Q34504839 | The medicalization of menopause: critique and consequences |
| Q33535652 | The menopause |
| Q38550074 | The menopause 'It's somewhere between a taboo and a joke'. A focus group study |
| Q35134598 | The menopause and HRT. Hormone replacement therapy, cardiovascular and cerebrovascular disease. |
| Q34229929 | The menopause and its treatment in perspective |
| Q35089975 | The menopause, hormone replacement therapy and breast cancer |
| Q46181781 | The menopause, hormone replacement therapy and informed consent: are women in an underresourced country adequately aware? |
| Q35948678 | The metabolic basis for the effects of HRT on coronary heart disease |
| Q34938339 | The metabolic syndrome in long-term cancer survivors, an important target for secondary preventive measures |
| Q37100398 | The molecular actions of oestrogen in the regulation of vascular health |
| Q40947254 | The need to do better - Are we still letting our patients down and at what cost? |
| Q34800158 | The new cholesterol guidelines. Applying them in clinical practice |
| Q33648148 | The number of X chromosomes influences protection from cardiac ischaemia/reperfusion injury in mice: one X is better than two. |
| Q34834758 | The overselling of hormone replacement therapy |
| Q32090066 | The phytoestrogen alpha-zearalenol reverses endothelial dysfunction induced by oophorectomy in rats |
| Q34592879 | The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum |
| Q58768337 | The protective effect of Er-Xian decoction against myocardial injury in menopausal rat model |
| Q49030574 | The protective effects of 17beta-estradiol against ischemia-reperfusion injury and its effect on pacing postconditioning protection to the heart |
| Q42634564 | The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. |
| Q77742270 | The puzzle of hormone replacement therapy (HRT) and cardiovascular disease (CVD) |
| Q33729775 | The relationship between sex hormones, sex hormone binding globulin and peripheral artery disease in older persons |
| Q35540369 | The risk of dementia in relation to statins and other lipid lowering agents. |
| Q35217988 | The risks and benefits of hormonal replacement therapy in healthy women and in breast cancer survivors |
| Q34011157 | The role of C-reactive protein in cardiovascular disease risk |
| Q74298673 | The role of C-reactive protein in cardiovascular disease risk |
| Q33757760 | The role of SERMs in the management of postmenopausal osteoporosis |
| Q43680109 | The role of cardiac registries in evidence-based medicine |
| Q35617189 | The role of estrogen in cardiovascular disease |
| Q36017502 | The role of estrogen on the pathology of cerebral aneurysms |
| Q37404662 | The role of estrogen receptor subtypes for vascular maintenance. |
| Q36864744 | The role of estrogens in control of energy balance and glucose homeostasis |
| Q34238238 | The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives |
| Q33870602 | The role of plaque rupture and thrombosis in coronary artery disease |
| Q34206981 | The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis |
| Q36304370 | The role of shear stress in the destabilization of vulnerable plaques and related therapeutic implications |
| Q78550526 | The role of treatment intentions and concerns about side effects in women's decision to discontinue postmenopausal hormone therapy |
| Q33792401 | The selective oestrogen receptor modulation: evolution and clinical applications |
| Q36349925 | The soy isoflavone genistein inhibits the reduction in Achilles tendon collagen content induced by ovariectomy in rats. |
| Q38108388 | The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 2: comparative risks |
| Q36781520 | The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective |
| Q36806086 | The timing hypothesis: Do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? |
| Q34585097 | The underuse of therapy in the secondary prevention of hip fractures |
| Q49791687 | The use and discontinuation of hormone replacement therapy in women in South China |
| Q35563218 | The use of estrogen in older women |
| Q37073904 | The use of pregabalin in the treatment of hot flashes |
| Q24793926 | The usefulness of information on HDL-cholesterol: potential pitfalls of conventional assumptions |
| Q57300844 | The validity of self-reported use of hormone replacement therapy among Danish nurses |
| Q80925982 | The value of phytoestrogens as a possible therapeutic option in postmenopausal women with coronary heart disease |
| Q79202505 | The women's health initiative postmenopausal hormone trials: overview and baseline characteristics of participants |
| Q33756911 | Theoretical basis for the benefit of postmenopausal estrogen substitution |
| Q90291071 | Therapeutic management of hyperlipoproteinemia (a) |
| Q46576596 | Therapeutic potential of oestrogen receptor ligands in development for osteoporosis |
| Q36892489 | Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. |
| Q28266853 | Therapy Insight: parenteral estrogen treatment for prostate cancer--a new dawn for an old therapy |
| Q36137967 | Therapy for stable angina in women |
| Q34025773 | Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications |
| Q35543467 | Thromboembolic Events in the Cancer Patient |
| Q73365337 | Thrombolytic therapy in the elderly |
| Q38117735 | Thrombosis in women: what are the knowledge gaps in 2013? |
| Q37276381 | Tibolone inhibits aortic atherosclerotic lesionformation in oophorectomized cholesterol-fed rabbits. |
| Q44272957 | Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux |
| Q24626206 | Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes |
| Q37438247 | Timing of estrogen replacement influences atherosclerosis progression and plaque leukocyte populations in ApoE-/- mice |
| Q33885656 | Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. |
| Q35971744 | Tissue-Specific Effects of Loss of Estrogen during Menopause and Aging. |
| Q33757754 | Tolerability profile of SERMs |
| Q37416880 | Total estrogen time and obstructive coronary disease in women: insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). |
| Q37015962 | Traditional management of chronic stable angina |
| Q36753585 | Trajectories of estradiol and follicle-stimulating hormone over the menopause transition and early markers of atherosclerosis after menopause |
| Q45279610 | Transdermal hormone replacement therapy and Doppler findings in normal and overweight postmenopausal patients |
| Q37385612 | Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies. |
| Q42525318 | Transdermal oestradiol replacement therapy enhances platelet constitutive nitric oxide synthase activity in postmenopausal women with type 2 diabetes mellitus. |
| Q47767259 | Transgender hormone therapy: understanding international variation in practice |
| Q35008013 | Transplantation of young ovaries restored cardioprotective influence in postreproductive-aged mice. |
| Q34303429 | Treating mixed dyslipidemias: why and how. |
| Q24793111 | Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities |
| Q36139976 | Treatment of Men for "Low Testosterone": A Systematic Review |
| Q34064046 | Treatment of anemia in heart failure: potential risks and benefits of intravenous iron therapy in cardiovascular disease |
| Q34336846 | Treatment of dyslipidemia in pre- and postmenopausal women with and without known atherosclerotic cardiovascular disease |
| Q36219667 | Treatment of menopausal symptoms post-Women's Health Initiative: refinement of existing treatments and development of new therapies |
| Q36213129 | Treatment of menopausal symptoms: what shall we do now? |
| Q34993510 | Treatment of peripheral arterial disease |
| Q34435633 | Treatment of postmenopausal osteoporosis: an evidence-based approach |
| Q34108983 | Treatment of the antiphospholipid antibody syndrome: progress in the last five years? |
| Q28191018 | Treatment of the elderly post-myocardial infarction patient |
| Q34389584 | Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions |
| Q33876807 | Treatment of the menopause: the swinging pendulum |
| Q44416274 | Treatment with hormone replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial |
| Q34232032 | Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010. |
| Q37669397 | Tubulointerstitial disease in diabetic nephropathy |
| Q90746949 | Two Cases of Acute Cholecystitis and Symptomatic Choledocholithiasis in Two Women Less than 40-Years-of-Age with Hormonal Intrauterine Devices |
| Q37610402 | Type and route of estrogen administration |
| Q39363360 | UK women doctors' use of hormone replacement therapy: 10-year follow up. |
| Q46861205 | Ubiquinol-cytochrome-c reductase 7.2 kDa protein of mitochondrial complex III is steroid-responsive and increases in cardiac hypertrophy and hypertension |
| Q44595554 | Under Treatment with Lipid-Lowering Drugs of High-Risk Coronary Heart Disease Patients of the GENICA Study |
| Q48564966 | Understanding physicians' attitudes towards hormone therapy |
| Q36655236 | Understanding the oestrogen action in experimental and clinical atherosclerosis. |
| Q33588350 | Update in internal medicine |
| Q37989179 | Update: estrogen and estrogen plus progestin therapy in the care of women at and after the menopause |
| Q38106748 | Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. |
| Q48671400 | Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health |
| Q35008617 | Updated recommendations for the diagnosis and management of osteoporosis: a local perspective |
| Q34476118 | Use and discontinuation of hormone replacement therapy in women with myocardial infarction: a nationwide study |
| Q47678169 | Use of evidence-based pharmacotherapy for secondary prevention of coronary heart disease: a Chinese medicine hospital versus a general hospital |
| Q33696204 | Use of hormone replacement therapy among cardiac patients at a Canadian academic centre |
| Q36149372 | Use of hormone replacement therapy by postmenopausal women after publication of the Women's Health Initiative Trial |
| Q42737503 | Use of postmenopausal estrogen replacement therapy from 1981 to 1997. |
| Q44095617 | Use of progestogen-only contraceptives/medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian Survey |
| Q37291566 | Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS) |
| Q46366785 | Validation of a decision model for preventive pharmacological strategies in postmenopausal women |
| Q37329802 | Validity and reliability of measurement instruments used in research. |
| Q33890813 | Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease |
| Q44349445 | Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin |
| Q35088138 | Variations in lipid levels according to menstrual cycle phase: clinical implications |
| Q37088243 | Vascular actions of estrogens: functional implications |
| Q36888620 | Vascular and metabolic effects of sex steroids: new insights into clinical trials |
| Q80833901 | Vascular cell signaling by membrane estrogen receptors |
| Q43787217 | Vascular effects of estrogen in type II diabetic postmenopausal women |
| Q35583311 | Vascular effects of estrogenic menopausal hormone therapy |
| Q73991166 | Vascular effects of estrogens: arterial protection versus venous thrombotic risk |
| Q34224777 | Vascular effects of hormones |
| Q44426065 | Vascular function of forearm microcirculation in postmenopausal women with type 2 diabetes: potential benefit of hormone replacement therapy? |
| Q34570432 | Vasculoprotective effects of oestrogens. |
| Q28204870 | Vasodilating effect of norethisterone and its 5 alpha metabolites: a novel nongenomic action |
| Q34727147 | Vasomotor and vascular effects of hormone replacement therapy |
| Q43080226 | Vasomotor hot flushes and 24-hour ambulatory blood pressure in normotensive women: A placebo-controlled trial on post-menopausal hormone therapy |
| Q43103032 | Vasomotor hot flushes and 24-hour ambulatory blood pressure in recently post-menopausal women |
| Q37610378 | Vasomotor symptoms and cardiovascular risk |
| Q43672796 | Venous endothelial function in postmenopausal women after six months of tibolone therapy |
| Q43929263 | Vitamin D receptor and estrogen receptor gene polymorphisms in postmenopausal Danish women: no relation to bone markers or serum lipoproteins |
| Q50858972 | Wellness in women after 40 years of age: the role of sex hormones and pheromones. |
| Q74341834 | What PROOF proves about calcitonin and clinical trials |
| Q34345261 | What are the priorities for managing cholesterol effectively? |
| Q74360902 | What do the statin trials tell us? |
| Q43856970 | What do we think about selective estrogen receptor modulators? |
| Q74195850 | What factors account for hormone replacement therapy prescribing frequency? |
| Q57277916 | What is evidence-based medicine? |
| Q35058238 | What is the cardioprotective role of hormone replacement therapy? |
| Q35583454 | What is the influence of hormone therapy on homocysteine and crp levels in postmenopausal women? |
| Q48070650 | What the future holds for women after menopause: where we have been, where we are, and where we want to go. |
| Q35082709 | What's in a risk factor? "He who strikes the ball". |
| Q53220661 | When practices, promises, profits, and policies outpace hard evidence: the post-menopausal hormone debate. |
| Q36350786 | Where are we with postmenopausal hormone therapy in 2005? |
| Q42767628 | Which clinical studies provide the best evidence? The best RCT still trumps the best observational study |
| Q47332234 | Why do professionals disagree? The case of hormone replacement therapy and coronary heart disease prevention |
| Q49068672 | Why perimenopausal women should consider to use a levonorgestrel intrauterine system |
| Q30417520 | Why primate models matter |
| Q39121531 | Women Stroke Association Statement on Stroke |
| Q43762464 | Women and cardiovascular risk |
| Q37622983 | Women and peripheral arterial disease |
| Q35025637 | Women at Risk for Coronary Heart Disease: How Research is Translated Into Innovation and Quality Outcomes at Kaiser Permanente. |
| Q34756066 | Women versus men with chronic atrial fibrillation: insights from the Standard versus Atrial Fibrillation spEcific managemenT studY (SAFETY). |
| Q44165039 | Women's Health Initiative study |
| Q44264779 | Women's angiographic vitamin and estrogen trial: design and methods |
| Q33722879 | Women's health |
| Q78856458 | Women's health and gender biology: the late but welcome arrival of evidence-based research |
| Q30329238 | Women's health care: a new paradigm for the 21st century. |
| Q37101516 | Women's health in menopause with a focus on hypertension |
| Q79299218 | Women's health issues |
| Q77386163 | Women's knowledge of hormone therapy |
| Q35229561 | X chromosome dosage and the response to cerebral ischemia |
| Q49477839 | Yoga Offers Cardiovascular Protection in Early Postmenopausal Women |
| Q80329306 | [AFSSAPS recommendations about menopause] |
| Q78784685 | [Androgens in menopausal women] |
| Q77812455 | [Approach of menopause in women at risk for breast cancer] |
| Q52552525 | [Atheroma plaque stabilization: a new concept based on the dynamic biology of atherosclerosis]. |
| Q82777135 | [Attitude to a post-menopausal woman who consults due to flushes and dyspareunia] |
| Q80903366 | [Cardiovascular risk in the "Women's Health Initiative". Much ado about nothing?] |
| Q73283471 | [Care for the menopausal woman: an objective to be developed from primary care] |
| Q81669735 | [Current role of hormone replacement therapy in the prevention of postmenopausal osteoporosis: gynecologic point of view] |
| Q80589015 | [Evidence based basis of decision making for or against a postmenopausal hormone treatment] |
| Q78573719 | [Experimental efficacy versus observational efficacy] |
| Q73943764 | [Genetics and quaternary prevention. The example of haemochromatosis] |
| Q74291358 | [Hormonal replacement therapy in Spain] |
| Q95721098 | [Hormone replacement therapy in ischemic heart disease prevention in women. Arguments against] |
| Q73940563 | [Hormone replacement therapy in menopause in question?] |
| Q79749465 | [Hypertension in women after menopause] |
| Q39329106 | [Menopausal hormone therapy]. |
| Q81318310 | [Postmenopausal hormone therapy and vascular risk] |
| Q81420397 | [Role of hormone-replacement therapy for prevention of coronary artery disease in women] |
| Q79780869 | [Should the menopause be treated?] |
| Q84341201 | [Surrogate end points--somewhere between essential and not worth discussing] |
| Q81591791 | [Update on menopause treatments, after recent controversies] |
| Q81285223 | [Who is responsible for providing us with the clinical practice guidelines?] |
| Q26829973 | 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Associat |